



} Faculté de médecine

Année 2022/2023

N°

## Thèse

Pour le

### DOCTORAT EN MEDECINE

Diplôme d'État

par

**Charlène LANDWERLIN**

Née le 9 juin 1994 à MULHOUSE (68)

---

**Comparaison des patients ayant fait un arrêt cardio-respiratoire extrahospitalier avec ou sans sus décalage du segment ST et place de la coronarographie chez ces patients :**

**une étude monocentrique rétrospective au CHU de Tours**

---

Présentée et soutenue publiquement le **7 septembre 2023** devant un jury composé de :

Président du Jury : Professeur Fabrice IVANES, Physiologie, Faculté de Médecine - Tours

Membres du Jury :

Professeur Antoine GUILLOU, Médecine intensive - réanimation, Faculté de Médecine – Tours

Docteur Christophe SAINT ETIENNE, Cardiologie, PH, CHU - Tours

Docteur Maëva GOURRAUD, Cardiologie, CCA, CHU - Tours

**Directeur de thèse : Professeur Denis ANGOULVANT, Cardiologie, Faculté de Médecine – Tours**

**UNIVERSITE DE TOURS  
FACULTE DE MEDECINE DE TOURS**

**DOYEN**  
**Pr Patrice DIOT**

**VICE-DOYEN**  
Pr Henri MARRET

**ASSESSEURS**

Pr Denis ANGOULVANT, *Pédagogie*  
Pr Mathias BUCHLER, *Relations internationales*  
Pr Theodora BEJAN-ANGOULVANT, *Moyens – relations avec l'Université*  
Pr Clarisse DIBAO-DINA, *Médecine générale*  
Pr François MAILLOT, *Formation Médicale Continue*  
Pr Patrick VOURC'H, *Recherche*

**RESPONSABLE ADMINISTRATIVE**

Mme Carole ACCOLAS

\*\*\*\*\*

**DOYENS HONORAIRES**

Pr Emile ARON (†) – 1962-1966  
*Directeur de l'Ecole de Médecine - 1947-1962*  
Pr Georges DESBUQUOIS (†) – 1966-1972  
Pr André GOUAZE (†) – 1972-1994  
Pr Jean-Claude ROLLAND – 1994-2004  
Pr Dominique PERROTIN – 2004-2014

**PROFESSEURS EMERITES**

Pr Daniel ALISON  
Pr Gilles BODY  
Pr Philippe COLOMBAT  
Pr Etienne DANQUECHIN-DORVAL  
Pr Luc FAVARD  
Pr Bernard FOUQUET  
Pr Yves GRUEL  
Pr Gérard LORETTE  
Pr Loïc VAILLANT

**PROFESSEURS HONORAIRES**

P. ANTHONIOZ – P. ARBEILLE – A. AUDURIER – A. AUTRET – C. BARTHELEMY – J.L. BAULIEU – C. BERGER – JC. BESNARD – P. BEUTTER – C. BONNARD – P. BONNET – P. BOUGNOUX – P. BURDIN – L. CASTELLANI – J. CHANDENIER – A. CHANTEPIE – B. CHARBONNIER – P. CHOUTET – T. CONSTANS – C. COUET – L. DE LA LANDE DE CALAN – P. DUMONT – J.P. FAUCHIER – F. FETISOF – J. FUSCIARDI – P. GAILLARD – G. GINIES – D. GOGA – A. GOUDEAU – J.L. GUILMOT – O. HAILLOT – N. HUTEN – M. JAN – J.P. LAMAGNERE – F. LAMISSE – Y. LANSON – O. LE FLOCHE – Y. LEBRANCHU – E. LECA – P. LECOMTE – AM. LEHR-DRYLEWICZ – E. LEMARIE – G. LEROY – M. MARCHAND – C. MAURAGE – C. MERCIER – J. MOLINE – C. MORAINA – J.P. MUH – J. MURAT – H. NIVET – D. PERROTIN – L. POURCELOT – R. QUENTIN – P. RAYNAUD – D. RICHARD-LENOBLE – A. ROBIER – J.C. ROLLAND – P. ROSSET – D. ROYERE – A. SAINDELLE – E. SALIBA – J.J. SANTINI – D. SAUVAGE – D. SIRINELLI – J. WEILL

## **PROFESSEURS DES UNIVERSITES - PRATICIENS HOSPITALIERS**

---

ANDRES Christian.....	Biochimie et biologie moléculaire
ANGOULVANT Denis .....	Cardiologie
APETOH Lionel .....	Immunologie
AUPART Michel.....	Chirurgie thoracique et cardiovasculaire
BABUTY Dominique .....	Cardiologie
BACLE Guillaume.....	Chirurgie orthopédique et traumatologique
BAKHOS David.....	Oto-rhino-laryngologie
BALLON Nicolas.....	Psychiatrie ; addictologie
BARBIER François.....	Médecine intensive et réanimation
BARILLOT Isabelle .....	Cancérologie ; radiothérapie
BARON Christophe .....	Immunologie
BEJAN-ANGOULVANT Théodora .....	Pharmacologie clinique
BERHOUET Julien .....	Chirurgie orthopédique et traumatologique
BERNARD Anne .....	Cardiologie
BERNARD Louis .....	Maladies infectieuses et maladies tropicales
BLANCHARD-LAUMONNIER Emmanuelle ....	Biologie cellulaire
BLASCO Hélène.....	Biochimie et biologie moléculaire
BONNET-BRILHAULT Frédérique .....	Physiologie
BOURGUIGNON Thierry .....	Chirurgie thoracique et cardiovasculaire
BRILHAULT Jean.....	Chirurgie orthopédique et traumatologique
BRUNEREAU Laurent .....	Radiologie et imagerie médicale
BRUYERE Franck.....	Urologie
BUCHLER Matthias.....	Néphrologie
CAILLE Agnès .....	Biostat., informatique médical et technologies de communication
CALAIS Gilles.....	Cancérologie, radiothérapie
CAMUS Vincent .....	Psychiatrie d'adultes
CORCIA Philippe.....	Neurologie
COTTIER Jean-Philippe .....	Radiologie et imagerie médicale
DEQUIN Pierre-François.....	Thérapeutique
DESMIDT Thomas .....	Psychiatrie
DESOUBEAUX Guillaume.....	Parasitologie et mycologie
DESTRIEUX Christophe .....	Anatomie
DI GUISTO Caroline .....	Gynécologie obstétrique
DIOT Patrice.....	Pneumologie
DU BOUEXIC de PINIEUX Gonzague .....	Anatomie & cytologie pathologiques
DUCLUZEAU Pierre-Henri.....	Endocrinologie, diabétologie, et nutrition
EHRMANN Stephan .....	Médecine intensive – réanimation
EL HAGE Wissam.....	Psychiatrie adultes
ELKRIEF Laure.....	Hépatologie – gastroentérologie
ESPITALIER Fabien.....	Anesthésiologie et réanimation, médecine d'urgence
FAUCHIER Laurent .....	Cardiologie
FOUGERE Bertrand .....	Gériatrie
FRANCOIS Patrick.....	Neurochirurgie
FROMONT-HANKARD Gaëlle .....	Anatomie & cytologie pathologiques
GATAULT Philippe.....	Néphrologie
GAUDY-GRAFFIN Catherine.....	Bactériologie-virologie, hygiène hospitalière
GOUPILLE Philippe .....	Rhumatologie
GUERIF Fabrice .....	Biologie et médecine du développement et de la reproduction
GUILLON Antoine.....	Médecine intensive – réanimation
GUILLON-GRAMMATICO Leslie.....	Epidémiologie, économie de la santé et prévention
GUYETANT Serge .....	Anatomie et cytologie pathologiques
GYAN Emmanuel.....	Hématologie, transfusion
HALIMI Jean-Michel.....	Thérapeutique
HANKARD Régis.....	Pédiatrie
HERAULT Olivier .....	Hématologie, transfusion
HERBRETEAU Denis .....	Radiologie et imagerie médicale
HOURIOUX Christophe.....	Biologie cellulaire
IVANES Fabrice .....	Physiologie
LABARTHE François .....	Pédiatrie
LAFFON Marc .....	Anesthésiologie et réanimation chirurgicale, médecine d'urgence
LARDY Hubert.....	Chirurgie infantile
LARIBI Saïd.....	Médecine d'urgence
LARTIGUE Marie-Frédérique .....	Bactériologie-virologie
LAURE Boris .....	Chirurgie maxillo-faciale et stomatologie
LECOMTE Thierry.....	Gastroentérologie, hépatologie

LEGRAS Antoine.....	Chirurgie thoracique
LESCANNE Emmanuel.....	Oto-rhino-laryngologie
LEVESQUE Éric.....	Anesthésiologie et réanimation chirurgicale, médecine d'urgence
LINASSIER Claude .....	Cancérologie, radiothérapie
MACHET Laurent .....	Dermato-vénéréologie
MAILLOT François .....	Médecine interne
MARCHAND-ADAM Sylvain .....	Pneumologie
MARRET Henri .....	Gynécologie-obstétrique
MARUANI Annabel .....	Dermatologie-vénérérologie
MEREGHETTI Laurent .....	Bactériologie-virologie ; hygiène hospitalière
MITANCHEZ Delphine .....	Pédiatrie
MOREL Baptiste .....	Radiologie pédiatrique
MORINIERE Sylvain.....	Oto-rhino-laryngologie
MOUSSATA Driffa .....	Gastro-entérologie
MULLEMAN Denis.....	Rhumatologie
ODENT Thierry.....	Chirurgie infantile
OUAISSE Mehdi .....	Chirurgie digestive
OULDAMER Lobna.....	Gynécologie-obstétrique
PAINTAUD Gilles .....	Pharmacologie fondamentale, pharmacologie clinique
PATAT Frédéric .....	Biophysique et médecine nucléaire
PERROTIN Franck .....	Gynécologie-obstétrique
PISELLA Pierre-Jean.....	Ophtalmologie
PLANTIER Laurent .....	Physiologie
REMERAND Francis .....	Anesthésiologie et réanimation, médecine d'urgence
ROINGEARD Philippe.....	Biologie cellulaire
RUSCH Emmanuel.....	Epidémiologie, économie de la santé et prévention
SAINT-MARTIN Pauline.....	Médecine légale et droit de la santé
SALAME Ephrem.....	Chirurgie digestive
SAMIMI Mahtab .....	Dermatologie-vénérérologie
SANTIAGO-RIBEIRO Maria .....	Biophysique et médecine nucléaire
SAUTENET-BIGOT Bénédicte .....	Thérapeutique
THOMAS-CASTELNAU Pierre .....	Pédiatrie
TOUTAIN Annick.....	Génétique
VELUT Stéphane .....	Anatomie
VOURC'H Patrick.....	Biochimie et biologie moléculaire
WATIER Hervé .....	Immunologie
ZEMMOURA Ilyess .....	Neurochirurgie

## **PROFESSEUR DES UNIVERSITES DE MEDECINE GENERALE**

---

DIBAO-DINA Clarisse  
LEBEAU Jean-Pierre

## **PROFESSEURS ASSOCIES**

---

MALLET Donatien ..... Soins palliatifs  
ROBERT Jean..... Médecine Générale

## **PROFESSEUR CERTIFIE DU 2<sup>ND</sup> DEGRE**

---

MC CARTHY Catherine.....Anglais

## **MAITRES DE CONFERENCES DES UNIVERSITES - PRATICIENS HOSPITALIERS**

---

AUDEMARD-VERGER Alexandra .....	Médecine interne
BISSON Arnaud .....	Cardiologie (CHRO)
BRUNAULT Paul .....	Psychiatrie d'adultes, addictologie
CARVAJAL-ALLEGRIA Guillermo .....	Rhumatologie (au 01/10/2021)
CLEMENTY Nicolas .....	Cardiologie
DOMELIER Anne-Sophie .....	Bactériologie-virologie, hygiène hospitalière
DUFOUR Diane .....	Biophysique et médecine nucléaire
FOUQUET-BERGEMER Anne-Marie.....	Anatomie et cytologie pathologiques
GARGOT Thomas .....	Physiologie
GOUILLEUX Valérie.....	Immunologie
HOARAU Cyrille .....	Immunologie
KERVARREC Thibault .....	Anatomie et cytologie pathologiques
LE GUELLEC Chantal.....	Pharmacologie fondamentale, pharmacologie clinique
LEDUCQ Sophie .....	Dermatologie
LEFORT Bruno .....	Pédiatrie
LEJEUNE Julien .....	Hématologie, transfusion
LEMAIGNEN Adrien .....	Maladies infectieuses
MACHET Marie-Christine .....	Anatomie et cytologie pathologiques
MOUMNEH Thomas .....	Médecine d'urgence
PARE Arnaud.....	Chirurgie maxillo-faciale et stomatologie
PIVER Éric.....	Biochimie et biologie moléculaire
ROUMY Jérôme .....	Biophysique et médecine nucléaire
STANDLEY-MIQUELESTORENA Elodie .....	Anatomie et cytologie pathologiques
STEFIC Karl .....	Bactériologie
TERNANT David .....	Pharmacologie fondamentale, pharmacologie clinique
VAYNE Caroline .....	Hématologie, transfusion
VUILLAUME-WINTER Marie-Laure .....	Génétique

## **MAITRES DE CONFERENCES DES UNIVERSITES**

---

AGUILLO-HERNANDEZ Nadia.....	Neurosciences
NICOGLOU Antonine .....	Philosophie – histoire des sciences et des techniques
PATIENT Romuald.....	Biologie cellulaire
RENOUX-JACQUET Cécile .....	Médecine Générale

## **MAITRES DE CONFERENCES ASSOCIES**

---

AUMARECHAL Alain .....	Médecine Générale
BARBEAU Ludivine.....	Médecine Générale
CHAMANT Christelle .....	Médecine Générale
ETTORI-AJASSE Isabelle.....	Médecine Générale
LAMARRE Valérie.....	Médecine Générale
LE GALLOU Laurence .....	Médecine Générale
PAUTRAT Maxime .....	Médecine Générale
RUIZ Christophe.....	Médecine Générale
SAMKO Boris.....	Médecine Générale

## **CHERCHEURS INSERM - CNRS - INRAE**

---

BECKER Jérôme.....	Chargé de Recherche Inserm – UMR Inserm 1253
BOUAKAZ Ayache .....	Directeur de Recherche Inserm – UMR Inserm 1253
BOUTIN Hervé.....	Directeur de Recherche Inserm – UMR Inserm 1253
BRIARD Benoit.....	Chargé de Recherche Inserm – UMR Inserm 1100
CHALON Sylvie .....	Directrice de Recherche Inserm – UMR Inserm 1253
DE ROCQUIGNY Hugues .....	Chargé de Recherche Inserm – UMR Inserm 1259
ESCOFFRE Jean-Michel.....	Chargé de Recherche Inserm – UMR Inserm 1253
GILOT Philippe.....	Chargé de Recherche Inrae – UMR Inrae 1282
GOMOT Marie.....	Chargée de Recherche Inserm – UMR Inserm 1253
GOUILLEUX Fabrice .....	Directeur de Recherche CNRS – EA 7501 - ERL CNRS 7001
GUEGUINU Maxime.....	Chargé de Recherche Inserm – UMR Inserm 1069
HEUZE-VOURCH Nathalie.....	Directrice de Recherche Inserm – UMR Inserm 1100
KORKMAZ Brice.....	Chargé de Recherche Inserm – UMR Inserm 1100
LATINUS Marianne.....	Chargée de Recherche Inserm – UMR Inserm 1253
LAUMONNIER Frédéric .....	Directeur de Recherche Inserm – UMR Inserm 1253
LE MERRER Julie .....	Directrice de Recherche CNRS – UMR Inserm 1253
MAMMANO Fabrizio.....	Directeur de Recherche Inserm – UMR Inserm 1259
MEUNIER Jean-Christophe .....	Chargé de Recherche Inserm – UMR Inserm 1259
PAGET Christophe .....	Directeur de Recherche Inserm – UMR Inserm 1100
RAOUL William .....	Chargé de Recherche Inserm – UMR Inserm 1069
SECHER Thomas.....	Chargé de Recherche Inserm – UMR Inserm 1100
SI TAHAR Mustapha .....	Directeur de Recherche Inserm – UMR Inserm 1100
SUREAU Camille .....	Directrice de Recherche émérite CNRS – UMR Inserm 1259
TANTI Arnaud .....	Chargé de Recherche Inserm – UMR Inserm 1253
WARDAK Claire.....	Chargée de Recherche Inserm – UMR Inserm 1253

## **CHARGES D'ENSEIGNEMENT**

---

### ***Pour l'éthique médicale***

BIRMELE Béatrice.....	Praticien Hospitalier
-----------------------	-----------------------

### ***Pour la médecine manuelle et l'ostéopathie médicale***

LAMANDE Marc .....	Praticien Hospitalier
--------------------	-----------------------

### ***Pour l'orthophonie***

BATAILLE Magalie.....	Orthophoniste
CLOTOUR Nathalie.....	Orthophoniste
CORBINEAU Mathilde.....	Orthophoniste
EL AKIKI Carole .....	Orthophoniste
HARIVEL OUALLI Ingrid.....	Orthophoniste
IMBERT Mélanie .....	Orthophoniste
SIZARET Eva .....	Orthophoniste

### ***Pour l'orthoptie***

BOULNOIS Sandrine .....	Orthoptiste
-------------------------	-------------

# SERMENT D'HIPPOCRATE

En présence des enseignants et enseignantes  
de cette Faculté,  
de mes chers condisciples  
et selon la tradition d'Hippocrate,  
je promets et je jure d'être fidèle aux lois de l'honneur  
et de la probité dans l'exercice de la Médecine.

Je donnerai mes soins gratuits aux indigents,  
et n'exigerai jamais un salaire au-dessus de mon travail.

Admis(e) dans l'intérieur des maisons, mes yeux  
ne verront pas ce qui s'y passe, ma langue taira  
les secrets qui me seront confiés et mon état ne servira pas  
à corrompre les mœurs ni à favoriser le crime.

Respectueux(euse) et reconnaissant(e) envers mes Maîtres,  
je rendrai à leurs enfants  
l'instruction que j'ai reçue de leurs parents.

Que les hommes et les femmes m'accordent leur estime  
si je suis fidèle à mes promesses.  
Que je sois couvert(e) d'opprobre  
et méprisé(e) de mes confrères et consœurs  
si j'y manque.

## Remerciements

### A mes maîtres et juges :

**A Monsieur le Professeur Denis ANGOULVANT**, un grand merci d'avoir accepté de diriger ce travail. Merci pour votre accompagnement et votre enseignement durant mon internat, ainsi que pour votre disponibilité et vos conseils avisés concernant la thèse et mes projets futurs.

**A Monsieur le Professeur Fabrice IVANES**, merci d'avoir accepté de présider ce sujet de thèse. Votre gentillesse et bienveillance m'ont marquée au cours de mon internat.

**A Monsieur le Professeur Antoine GUILLOON**, merci de me faire l'honneur de juger ce travail par vos qualités de réanimateur.

**A Monsieur le Docteur Christophe SAINT ETIENNE**, merci de me faire l'honneur de faire partie de mon jury. Merci pour ta disponibilité, ton enseignement et ton enthousiasme pour la cardiologie interventionnelle, que tu nous partages au quotidien.

**A Madame le Docteur Maëva GOURRAUD**, merci d'avoir accepté de faire partie de mon jury. Dès mes débuts au CHU, tu as été un modèle et un soutien de taille. Ta rigueur et ta force de travail sont impressionnantes. Merci de m'avoir accompagnée et conseillée avec tant de gentillesse et bienveillance. J'ai énormément appris à tes côtés, aussi bien humainement que professionnellement, et j'espère pouvoir apprendre encore davantage. Bien plus qu'une chef, tu es devenue une amie, merci pour tout.

### Aux cardiologues rencontrés au cours de mon internat, du CHU et d'ailleurs :

**A Monsieur le Professeur Dominique BABUTY**, vos connaissances sont immenses et votre bienveillance envers les internes est encore plus grande. Apprendre à vos côtés a été une chance et vos visites resteront un des meilleurs moments d'apprentissage de mon internat.

**A Monsieur le Professeur Laurent FAUCHIER**, merci pour votre enseignement et accompagnement durant mon internat.

**A Madame le Professeur Anne BERNARD**, merci pour votre enseignement avec rigueur et passion de l'échocardiographie.

**A Madame le Professeur Theodora BEJAN-ANGOULVANT**, merci pour votre aide précieuse dans ce travail et pour votre pédagogie dans l'apprentissage des bases statistiques.

**A Monsieur le Docteur Régis DETURCK**, merci infiniment de m'avoir accompagnée et guidée avec tant de bienveillance, au tout début de mon internat. Vos connaissances, votre empathie et humilité m'ont marquée à jamais, et j'espère un jour vous ressemblez.

A l'ensemble des chefs de cardiologie du CHU, **Dr CLERC, Dr DION et Dr PIERRE** pour vos enseignements et votre bonne humeur, à **Jérémie, Thibaud, Walid** pour le semestre en USIC, à **Arnaud** pour les « réflexes », et à **Alexandre et Nicolas** pour le semestre en HC.

**A Carl**, merci pour toute ta bienveillance, pour tes conseils avisés, pour ta disponibilité et ta pédagogie lors des staffs coro.

**A Pascal**, merci pour tes conseils, ta disponibilité et ta persévérance à m'apprendre les bases de la rythmologie.

**A Alexandre GAMET**, merci pour avoir été un des premiers à me faire découvrir la coronarographie et à m'encourager dans cette voie.

**Aux équipes médicales de cardiologie de Blois, d'Orléans, de réanimation médicale d'Orléans, de réanimation cardiaque du CHU**, merci de m'avoir accueillie, encadrée, et d'avoir contribué à ma formation avec autant de bienveillance.

**Aux équipes paramédicales, de jour comme de nuit**, rencontrées lors de mes différents stages, vous côtoyer a toujours été un plaisir, merci pour votre humour et votre bonne humeur collective.

Une pensée toute particulière pour **Marine L. et Pauline S.**, devenues des amies, avec qui partir au ski est toujours un plaisir, et à **l'équipe d'USCI du CHU de jour et de nuit** (Sandra, Laurence, Margaux, Christelle...).

**A l'équipe du plateau de coronarographie du CHU**, merci pour votre accueil toujours chaleureux quel que soit l'heure du jour ou de la nuit.

### **A mes co-internes devenus des amis,**

**A Inès**, de toutes les personnes rencontrées durant mon internat, tu es et resteras ma plus belle rencontre tourangelle. De co-interne, tu es devenue ma meilleure amie, ma confidente, ma « colocataire », mille mercis pour ton amitié si sincère, pour ta bonne humeur constante, et ton soutien en toute circonstance. A tous nos souvenirs partagés ensemble à l'hôpital et en dehors, à tous nos fous rires, et à tous ceux à venir que j'ai hâte de partager avec toi.

**A Mathieu**, de nos débuts à Orléans, en tant que co-interne et voisin, à nos futurs pas ensemble en tant que Docteur Junior, toi le roi des soirées blind test, jeux de société et Nintendo Switch, merci pour ton amitié, ton authenticité et ton humour piquant.

**A Ivann**, qu'aurait été le semestre en HC sans toi, merci de m'avoir fait rire et supporté pendant ces six mois. Ton soutien est sans faille.

**A Marine**, quel plaisir d'entendre ton rire si inimitable au détour d'un couloir. Ne change pas.

**A Roxane et Marie**, merci pour tous vos précieux conseils lors de nos stages à Blois et Orléans, que j'écoutes si attentivement. Vous êtes deux filles aux caractères bien différents, mais avec un point commun : un cœur en or. Merci pour tout.

**A Claire et Ahmad**, avec votre bonne humeur permanente et vos personnalités si différentes, vous avez égaillé mon internat. Ne changez rien.

Merci à **Yassine** pour ta gentillesse et tes incroyables connaissances en rythmologie. Merci à **Thibault** pour avoir été un modèle et un chef de garde au top. Merci à **Mickaël** pour le semestre d'USCI (envers et contre tout).

Merci à tous les autres internes de cardiologie rencontrés durant mon internat, des plus anciens déjà thésés, **Jean-Baptiste** (et ton aide pour ce travail), **Mathieu, Antonin, Kassem, Amélie**, aux plus jeunes, **Lucile, Pierre, Sami, Lisa, Paul, Younes, Dylan, Constance, Alexandre, Mathieu**, ....

Merci à **mes co-internes de réanimation à Orléans (Inès, Alice, Fanny, Chemsa, William, Clément, Jonathan)**, sans qui la découverte de la réanimation aurait été bien moins drôle.

Merci à **Stéphane, Germain, Benjamin et Sonia** pour les bons moments passés en réanimation CCV à vos côtés. Et merci à **Élise** pour le semestre passé ensemble à Orléans.

Sans vous tous, l'internat aurait été bien plus fade, loin de mon « chez moi alsacien », merci pour tout.

#### **A mes amis strasbourgeois,**

- **Gatien, Sara**, rencontrés sur les bancs de la fac, vous avez égaillé mon externat, et dix ans plus tard, je suis ravie de vous compter toujours parmi mes amis les plus proches. Nos chemins se sont séparés à l'internat, pour devenir de votre côté, chirurgien ou radiologue. Mais peu importe la distance, de Hanoï, à Strasbourg, en passant par Paris, Nancy ou Tours, les souvenirs restent et notre amitié perdure. Merci pour tout, j'ai hâte de voir ce que les dix prochaines années nous réservent.

- **Juliette**, « ma juju », notre amitié a été un repère depuis le début, merci pour ton soutien et ton oreille toujours attentive durant ces dix dernières années. Merci pour tous nos voyages et aventures ensemble à travers l'Europe. Comme on dit, loin des yeux mais pas loin du cœur.

#### **A ma famille :**

**A mes parents, Papa, Maman**, merci de m'avoir toujours encouragée dans mes choix et décisions. Vous avez toujours été mes premiers soutiens, du premier jour de médecine à aujourd'hui, vous m'avez accompagnée de près ou de loin, dans les bons et moins bons moments, en me rappelant sans cesse « que l'on travaille pour soi ». Sans vous, sans votre aide si précieuse, et votre amour infaillible, cela n'aurait pas été possible. Mille mercis, je vous en serai infiniment reconnaissante.

**A ma sœur, Pauline**, nos chemins se sont séparés après la première année de médecine mais tu as toujours été à mes côtés, prête à m'écouter et me réconforter, toi qui me connais par cœur. Nos caractères si différents nous rapprochent. Après tes deux doctorats soutenus avec brio, à mon tour de

passer ce cap, avec toi, toujours à mes côtés.

**A ma grand-mère, Nicole et à mes grands-parents, Alice, Roger et Paul** partis trop tôt, j'espère vous avoir rendu fiers, pas un jour ne passe sans penser à vous, merci pour tout.

## Table of contents

<i>Résumé</i> .....	12
<i>Abstract</i> .....	14
<i>Abbreviations</i> .....	16
<i>Introduction</i> .....	17
<i>Materials and Methods</i> .....	19
TRIAL DESIGN AND OVERSIGHT .....	19
PATIENTS .....	19
PATIENT CHARACTERISTICS AND TREATMENT.....	20
PRIMARY AND SECONDARY END POINTS.....	21
STATISTICAL ANALYSIS .....	22
<i>Results</i> .....	23
PATIENT CHARACTERISTICS .....	23
CARDIAC ARREST CIRCUMSTANCES .....	24
ECG .....	25
TREATMENTS .....	26
ICU .....	27
PRIMARY AND SECONDARY END POINTS.....	29
UNIVARIATE AND MULTIVARIATE SURVIVAL ANALYSIS .....	30
NORMAL CAG.....	32
NSTE-CULPRIT LESION-REVASCULARIZATION.....	32
EVOLUTION BY YEAR .....	33
<i>Discussion</i> .....	34
<i>Conclusion</i> .....	40
<i>Bibliography</i> .....	41
<i>Supplementary data</i> .....	45
<i>Page de signatures</i> .....	56
<i>Dépôt de thèse</i> .....	57

## Résumé

**Comparaison des patients ayant fait un arrêt cardio-respiratoire extrahospitalier avec ou sans sus décalage du segment ST et place de la coronarographie chez ces patients : une étude monocentrique rétrospective au CHU de Tours**

### Objectif

L'infarctus du myocarde est une des principales causes d'arrêt cardiaque extrahospitalier (ACR-EH). Cependant, la place de la coronarographie en urgence, bien établie dans les infarctus du myocarde avec sus-décalage du segment ST (ACR-EH-ST+), reste incertaine dans certaines situations et notamment, celles des ACR-EH sans sus-décalage du segment ST (ACR-EH-ST-).

Les dernières recommandations de l'ESC et de l'ACC/AHA ne définissent pas clairement le délai optimal de la coronarographie dans les ACR-EH-ST-. Ces dernières années, trois essais randomisés (COACT, 2019 / TOMAHAWK, 2021 / EMERGE, 2022) ont étudié la place de la coronarographie (en urgence vs différée) chez les patients ACR-EH-ST-, mais n'ont pas réussi à montrer un bénéfice sur la mortalité de la coronarographie en urgence.

### Matériel et méthode

Notre étude rétrospective monocentrique au CHU de Tours, sur les dix dernières années, de janvier 2012 à décembre 2022, étudie l'impact clinique de la réalisation immédiate de la coronarographie chez les patients ayant fait un ACR-EH avec ou sans ST+ à l'électrocardiogramme, ainsi que l'évolution de nos pratiques.

Notre étude a inclus tous les patients consécutifs pris en charge pour ACR-EH et adressés directement en salle de coronarographie après récupération d'une activité cardiaque. Ils ont été répartis en deux sous-groupes : ACR-EH-ST+ et ACR-EH-ST-. Notre principal critère de jugement était la mortalité toute cause à 30 jours. Les critères de jugement secondaires étaient le score de Glasgow à l'admission en réanimation, la durée de l'hospitalisation en réanimation, la durée d'intubation, la durée du support inotrope et les critères secondaires de sécurité étaient un saignement majeur, un AVC, des troubles du rythme ventriculaire et une insuffisance rénale aigüe nécessitant un recours à la dialyse.

## Résultats

237 patients pris en charge pour ACR-EH ont été inclus, dont 124 ACR-EH-ST+ et 113 ACR-EH-ST-. Les patients ACR-EH-ST- étaient significativement plus âgés et plus à risque, avec plus souvent des antécédents de maladie cardiovasculaire, que les patients ACR-EH-ST+. A 30 jours, 53 (43%) patients du groupe ACR-EH-ST+ et 64 (57%) patients du groupe ACR-EH-ST- étaient décédés ( $p<0,05$ ). La réalisation en urgence de la coronarographie post ACR-EH retarde l'admission en unité de réanimation et la mise en place des mesures de neuroprotection (avec un temps moyen de transfert de 100 minutes compte tenu de la distance entre la salle de coronarographie et l'unité de réanimation dans notre CHU), ce qui pourrait expliquer en partie la surmortalité du groupe ACR-EH-ST-, chez qui seulement 21% de lésions coronaires coupables ont été retrouvées. En analyse multivariée, seuls l'âge et l'absence de rythme choquable restaient des prédicteurs de mortalité.

## Conclusion

La prise en charge des ACR-EH suspects d'une étiologie cardiaque dans notre centre est cohérente avec les résultats des dernières recommandations et études. Le recours à la coronarographie en urgence semble plus bénéfique chez les patients avec sus décalage post resuscitation. Notre étude n'a pas réussi à identifier de nouveaux facteurs prédictifs permettant de mieux sélectionner les patients avec un ST- post ACR-EH pouvant bénéficier de la coronarographie en urgence avant l'admission en réanimation.

## Mots clés

Arrêt cardiaque extrahospitalier, sous-décalage, sus-décalage, coronarographie, maladie coronaire, lésion coronaire coupable, neuroprotection, mortalité toute cause

## Abstract

### **Comparison of emergency coronary angiography in ST elevation and non-ST elevation out-of-hospital cardiac arrest patients: a monocenter retrospective study**

#### **Background**

Myocardial infarction is one of the major cause of out-of-hospital cardiac arrest (OHCA). However, the place of immediate coronary angiography (CAG), clearly indicated in ST-segment elevation myocardial infarction (STEMI), remains uncertain with other clinical presentations such as non ST elevation (NSTE), acute coronary syndrome these last years. ESC and ACC/AHA guidelines do not clearly define the timing of CAG in OHCA without STEMI. Three recent prospective randomized trials COACT (2019), TOMAHAWK (2021) and EMERGE (2022) did not prove a benefit of an immediate CAG over a delayed CAG with respect to 30-day risk of death from any cause in NSTE-OHCA patients.

#### **Objective**

Our retrospective study seeks to assess the clinical impact of immediate coronary angiography in OHCA patients, with or without ST-segment elevation in University hospital of Tours during the last decade, in order to compare our practice and results to these recent randomized studies.

#### **Materials and Methods**

This monocentric retrospective observational study was based on a cohort of 237 patients, who were referred to the catheterization laboratory for an immediate coronary angiography after an out-of-hospital cardiac arrest, from January 2012 to December 2022, in the university hospital center of Tours, in France. A subgroup analysis was performed according to post resuscitation ECG (STE-OHCA group and NSTE-OHCA group). Our main end point was death from any cause at 30 days. Our secondary efficacy end points were neurological deficit (Glasgow Coma Scale at the discharge of the ICU), length of stay in the ICU, length of mechanical ventilation, length of inotropic support, and our secondary safety end points were severe bleeding, stroke, ventricular tachycardia, and acute kidney failure leading to renal-replacement therapy.

## **Results**

At 30 days, 53 of 124 patients (43%) in the STE-OHCA group and 64 of 113 patients (57%) in the NSTE-OHCA group had died ( $p<0,05$ ). Immediate CAG in OHCA with cardiac cause (STE or No STE group) in our center postpones ICU admission and neuroprotection management (median time of transfer around 100 minutes), which could explain the higher mortality in NSTE-OHCA group, as coronary culprit lesion was only identified in 21% of these patients. Multivariate analysis showed that both age and absence of shockable first monitored rhythm after resuscitation remained the only significant predictors of mortality at 30 days.

## **Conclusion**

Management of OHCA patients with cardiac cause (ST elevation or Non ST elevation) in our center is consistent with observed shift of scientific societies recommendations during the last decade, as we saw an evolution in the profile of patient undergoing an immediate CAG after OHCA (exclusively the STE-OHCA). Our retrospective study failed at identifying predictive factors of a benefit of early CAG in NSTE-OHCA patients.

## **Key words**

Out-of-hospital cardiac arrest, Non-ST elevation, ST elevation, coronary angiography, coronary artery disease, culprit lesion, neuroprotection, death from any cause

## Abbreviations

BBB: Bundle Branch Block

BMI : Body Mass Index

CAG: Coronary Angiography

CABG : Coronary Artery Bypass Grafting

Cath Lab : Catheterization Laboratory

CPC Scale : Cerebral Performance Categories Scale

CPR : CardioPulmonary Resuscitation

ECG : Electrocardiogram

EEC : External Electric Shock

GCS : Glasgow Coma Scale

ICU: Intensive Care Unit

LF: Low Flow

NF: No Flow

NSE : Neuron Specific Enolase

NSTE: No ST Segment Elevation

NSTE-OHCA: No ST Segment Elevation – Out of Hospital Cardiac Arrest

OHCA: Out-of-Hospital Cardiac Arrest

PCI : Percutaneous Coronary Intervention

STE: ST Segment Elevation

STE-OHCA: ST Segment Elevation – Out of Hospital Cardiac Arrest

STEMI : ST- Elevation Myocardial Infarction

VT : Ventricular Tachycardia

## Introduction

Out-of-hospital cardiac arrest (OHCA) is a frequent cause of death worldwide and thus a major public health issue. More than 40,000 patients suffer from OHCA in France every year (i.e. one OHCA every 10 minutes<sup>1</sup>), with an estimated 300,000 OHCA per year in Europe<sup>2</sup>, and almost 350,000 OHCA per year in the United States of America<sup>3</sup>.

The prognosis of OHCA is poor and frequently associated with a low survival rate. Indeed, despite the advances in cardiopulmonary resuscitation (CPR) and the progression in emergency and intensive care, mortality remains high. Return to spontaneous circulation after cardiac arrest only occurs in 30% of OHCA, and few patients arrive alive at the hospital (22%). In-hospital survival is estimated at 8%, with subsequent one-month survival rate of 10% and a one-year survival rate of 7,7%<sup>2,4</sup>.

Cardiac cause is found in 65% of all cardiac arrests<sup>5</sup>. In most cases (80%), acute coronary syndrome or chronic coronary syndrome is found to be responsible of the cardiac arrest, before non-ischemic related ventricular arrhythmia<sup>6</sup>. The place of coronary angiography (CAG) is critical and plays a central role in patient care, as early revascularization improves survival rate and prognosis in patients with severe acute myocardial ischemia<sup>7</sup>. However, even if the timing of the CAG in OHCA with ST segment elevation (STE-OHCA) is clear<sup>8</sup>, it is less evident for OHCA without STE (NSTE-OHCA)<sup>9-12</sup>. Even though early revascularization has proved its efficacy by reducing mortality and improving cardiac prognosis, the place of intensive care management of cardiorespiratory arrest also plays an important role<sup>13</sup>, especially cerebral neuroprotection (survival rate without neurological deficit is improved by early neuroprotection care).

Thus, transferring OHCA patient to a cath lab for an emergency CAG is likely to delay intensive care unit (ICU) admission and initiation of neuroprotection strategies. ESC and ACC/AHA guidelines<sup>14-16</sup> do not clearly define the timing of CAG in NSTE-OHCA patients management.

Since 2018, several randomized controlled trials investigating the timing of CAG in patients with NSTE-OHCA were published<sup>17-19</sup>. Among them, three large randomized prospective clinical trials, COACT (2019)<sup>20</sup>, TOMAHAWK (2021)<sup>21</sup> and EMERGE (2022)<sup>22</sup>

specifically investigated the question of immediate versus delayed CAG in NSTE-OHCA patients.

These studies did not show a significant benefit of immediate vs delayed CAG in NSTE-OHCA patients. There was no statistical difference on the overall survival at 30 or 90 days. These information are important for pre hospital health care professional, emergency physician and interventional cardiologist in charge of triaging and managing NSTE-OHCA patients. The decision to transfer the patients to the cath lab before the ICU may impact its prognosis, especially in a situation where both facilities are not at the same hospital.

As this is the case in our university hospital, we performed a retrospective clinical study on resuscitated OHCA patients referred for emergency CAG to our cath lab in the last 10 years.

## Materials and Methods

### TRIAL DESIGN AND OVERSIGHT

The study was designed as a monocentric retrospective observational study. The study enrolled a cohort of all consecutive patients who were referred to the catheterization laboratory for an immediate coronary angiogram after a resuscitated OHCA without exclusion criteria, from January 2012 to December 2022, in the university hospital center of Tours, in France.

### PATIENTS

Patients were eligible for the study if they had been referred to the cath lab for a fast track CAG after an out of hospital cardiac arrest followed by the recuperation of spontaneous rhythm. Decision to perform an immediate CAG was taken jointly by the cardiologist, the emergency and the intensive care physicians.

Patients were eligible only if post CAG hospitalization was in one of the different ICU of the university hospital of Tours. Exclusion criteria were in-hospital cardiac arrest (in operating room, in emergency department...), no hospitalization in ICU after the CAG, death before the arrival in ICU, or obvious non-coronary cause of the cardiac arrest (sepsis...).

Data were gathered from our (CardioReport™, MediReport, cath lab data base) and from our electronic clinical record manager (DPP, Cerner, Millenium®).

380 patients were recorded on our cath lab database for “cardiac arrest” from January 2012 to December 2022. 237 (62%) patients were enrolled following our inclusion criteria (OHCA with a suspected coronary cause leading to immediate CAG) and 143 (38%) were excluded (48 (13%) because of in hospital cardiac arrest, 38 (10%) were hospitalized in ICU in another hospital of Loire Valley, 15 (4%) did not have cardiac arrest, 13 (3%) died before the admission in ICU, 9 (2%) had a delayed CAG and 20 (5%) for other cause) (Figure 1).

380 OHCA patients underwent CAG  
between January 1, 2012, and December 31, 2022 at  
University Hospital of Tours

- 143 Excluded :
- 48 were in hospital cardiac arrest
  - 38 were hospitalized in ICU in other hospital of Loire Valley
  - 15 were STEMI without cardiac arrest
  - 13 died before admission in ICU
  - 9 had delayed CAG
  - 20 had other causes

237 OHCA patients who underwent CAG and ICU hospitalization in University Hospital of Tours

124 OHCA  
with STE

113 OHCA  
without STE (NSTE)

- 48 patients with ischemia sign on ECG
- 65 patients without repolarization abnormalities

**Figure 1. Flow Chart of the study**

## PATIENT CHARACTERISTICS AND TREATMENT

The main patient characteristics studied were age, sex, body mass Index (BMI), cardiovascular risk factors, previous coronary or peripheral artery disease, previous percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), previous stroke, heart surgery or chronic kidney or respiratory failure.

The circumstances of the cardiac arrest were collected (arrest witnessed, bystander cardiopulmonary resuscitation, shockable first monitored rhythm, median time from arrest to basic life support (no flow), median time from arrest to return of spontaneous circulation (low flow)).

Post resuscitation first ECG analysis was retrieved from the physician's interpretation recorded in the medical report (sign of ischemia, rhythm, repolarization abnormality). Following our local protocol, an echocardiography was realized, if possible, at the arrival of the patient in the cath lab. The CAG retrospectively collected data were the median time from arrest to CAG, the median time of the CAG, the catheterization access, the severity of coronary artery disease, the identification of the culprit lesion (defined as a severe artery stenosis at least of 70% or occlusion), the revascularization treatment, and the median amount of contrast dye. In patients with multivessel disease, the choice of revascularization strategy was at the discretion and local protocol of the individual cath lab operator. In ICU, Glasgow Coma scale, temperature and biological laboratory values were collected from electronic clinical report for each patient. Post resuscitation care was in line with international and European resuscitation guidelines. Targeted temperature management was initiated as soon as possible and was performed in accordance with local protocol of the different ICU of the University hospital of Tours (medical ICU, surgical ICU, cardiac surgical ICU, URTC ICU). Prevention and control of secondary cerebral injury of systemic origin were managed according to guidelines. In patient with persistent coma, the life sustaining treatment was based on local practice.

## PRIMARY AND SECONDARY END POINTS

We first studied the cohort and then divided it into two groups based on post-resuscitation ECG analysis. The first group included all the patients with ST elevation (STE-OHCA group) and the second group, all patients without ST elevation (NSTE-OHCA group). We compared each groups. Our main end point was death from any cause at 30 days. Our secondary efficacy end points were neurological deficit (Glasgow Coma Scale at the discharge of the ICU), length of hospitalization in ICU, length of mechanical ventilation, length of inotropic support. Our secondary safety end points were severe bleeding, stroke, ventricular tachycardia, acute kidney failure leading to renal-replacement therapy. We also defined biological secondary endpoints by using a median creatinine peak level, a median troponin ratio and median NSE level usually measured at 2-3 days of ICU hospitalization. The troponin ratio was calculated by the troponin level divided by the standardized level norm, as the bioassay of troponin changed during the years (troponin I and then troponin T hs), as well as the standardized norms (<0,07 for the troponin I and <14 for troponin T hs).

## STATISTICAL ANALYSIS

Categorical variables are expressed as percentages. Quantitative variables are expressed as median with IQR. We used Chi2 Test to compare categorical variables and Student T test to compare quantitative variables. Logistic regression was used for univariate analysis and for multivariate analysis, on R software (R Core Team, 2020). A difference was considered significant, if the p value was less than 0,05 ( $p<0,05$ ).

## Results

From January 2012 to December 2022, we retrospectively enrolled 237 patients who had been successfully resuscitated after OHCA and were immediately referred to the cath lab of University hospital of Tours for emergency CAG.

124 patients (52%) had a ST-segment elevation on ECG (STE-OHCA group) and 113 patients (48%) did not have a ST-segment elevation on ECG after resuscitation (NSTE-OHCA group).

### PATIENT CHARACTERISTICS

The baseline characteristics are shown in Table 1. Median age was 63 years, with a majority of men (76%) with a high cardiovascular risk.

**Table 1 . Baseline Characteristics of the Cohort**

	COHORT (N= 237)
<b>Median age (IQR) – year</b>	63 (51-71)
<b>Male sex -no. (%)</b>	180 (76)
<b>Median BMI (IQR) – kg/m2</b>	27 (24-31)
<b>Cardiovascular risk – no. (%)</b>	
• Diabetes mellitus	45 (19)
• Hypertension	114 (48)
• Current smoker	79 (33)
• Dyslipidemia	76 (32)
<b>Previous coronary artery disease – no. (%)</b>	35 (15)
<b>Previous peripheral artery disease – no. (%)</b>	14 (6)
<b>Previous PCI – no. (%)</b>	26 (11)
<b>Previous CABG – no. (%)</b>	7 (3)
<b>Previous stroke – no. (%)</b>	9 (4)
<b>Previous heart surgery – no. (%)</b>	8 (3)
<b>Chronic kidney failure – no. (%)</b>	5 (2)
<b>Chronic respiratory failure – no. (%)</b>	1 (0,4)

In our subgroups analysis, baseline characteristics were quite similar between groups except for age and past history of coronary artery disease. Patients of the NSTE-OHCA group were significantly older (65 [55-76] versus 58 [50-69], p=0,01). There was also a statistically significant difference between STE-OHCA group and NSTE-OHCA group regarding the proportion of previous coronary artery disease (10% in STE-OHCA group vs 20% in NSTE-OHCA group, p<0,05). Thus, we observed that the number of previous PCI was higher as well in NSTE-OHCA group (Table 2). This is consistent with a higher proportion of patients receiving baseline aspirin medication in NSTE-OHCA group than in STE-OHCA group (p<0,05) (Table 11).

**Table 2. Comparison of baseline Characteristics of the Patients**

	STE-OHCA (N= 124)	NSTE-OHCA (N=113)	p-value
<b>Median age (IQR) – year</b>	58 (50-69)	65 (55-76)	<b>0,01</b>
<b>Male sex – no. (%)</b>	94 (76)	83 (73)	0,92
<b>Median BMI (IQR) – kg/m2</b>	27 (24-31)	27 (23-30)	0,36
<b>Cardiovascular risk – no. (%)</b>			
• Diabetes mellitus	18 (15)	26 (2)	0,10
• Hypertension	55 (45)	58 (51)	0,70
• Current smoker	45 (37)	33 (29)	0,23
• Dyslipidemia	33 (27)	42 (37)	0,09
<b>Previous coronary artery disease – no. (%)</b>	12 (10)	23 (20)	<b>&lt; 0,05</b>
<b>Previous peripheral artery disease – no. (%)</b>	5 (4)	9 (8)	0,32
<b>Previous PCI – no. (%)</b>	8 (7)	18 (16)	<b>&lt; 0,05</b>
<b>Previous CABG – no. (%)</b>	2 (2)	5 (4)	0,26
<b>Previous stroke – no. (%)</b>	7 (6)	2 (2)	0,18
<b>Previous heart surgery – no. (%)</b>	4 (3)	4 (4)	1,00
<b>Chronic kidney failure – no. (%)</b>	0 (0)	5 (4)	<b>&lt; 0,05</b>
<b>Chronic respiratory failure – no. (%)</b>	0 (0)	1 (1)	0,48

## CARDIAC ARREST CIRCUMSTANCES

In our cohort, a witness was present in 84% of OHCA. 73% of patients benefited from cardiopulmonary resuscitation initiated by a bystander and 69% had a shockable first monitored rhythm. No Flow (NF) and Low Flow (LF) median durations were respectively 5 minutes and 20 minutes (Table 3).

**Table 3. Cardiac arrest circumstances in the cohort**

	COHORT (N= 237)
<b>Arrest witnessed – no. (%)</b>	200 (84)
<b>Bystander CPR – no. (%)</b>	174 (73)
<b>Shockable first monitored rhythm – no. (%)</b>	163 (69)
<b>Median time from</b>	
• arrest to basic life support ( <b>No Flow</b> ) (IQR) – min	5 (1-10)
• arrest to return of spontaneous circulation ( <b>Low Flow</b> ) (IQR) – min	20 (13-27)

In the STE-OHCA and NSTE-OHCA groups, there were no significant differences regarding the presence of a witness or the initiation of cardiopulmonary resuscitation by a bystander. The two significant differences were a higher frequency of shockable first monitored rhythm in STE-OHCA group (77% vs 58%, p<0,001) and a shorter median NF duration (3 min vs 5 min, p<0,05) (Table 4).

**Table 4. Comparison of cardiac arrest circumstances between STE-OHCA and NSTE-OHCA**

	STE-OHCA (N= 124)	NSTE-OHCA (N=113)	p-value
<b>Arrest witnessed – no. (%)</b>	104 (84)	92 (81)	1,00
<b>Bystander CPR – no. (%)</b>	95 (77)	75 (66)	0,19
<b>Shockable first monitored rhythm – no. (%)</b>	95 (77)	65 (58)	< 0,001
<b>Median time from</b>			
• arrest to basic life support ( <b>No Flow</b> ) (IQR) – min	3 (0-5)	5 (1-10)	< 0,05
• arrest to return of spontaneous circulation ( <b>Low Flow</b> ) (IQR) – min	20 (12-28)	20 (14-30)	0,62

## ECG

In our cohort, post resuscitation ECG analysis shows a majority of narrow QRS (69%). Repolarization abnormalities were localized in anterior and inferior leads (18% each) (Figure 5. in Supplementary data).

Post resuscitation ECG analysis shows that ischemia signs were more frequently localized in anterior (29%) and inferior (31%) leads with narrow QRS (85%) in the STE-OHCA group than in NSTE-OHCA group, where narrow QRS were significantly less frequent (51%) and lateral localization ischemia was predominant (12%) (Figure 5. in Supplementary data).

## TREATMENTS

Details about procedures, severity of coronary artery disease and treatments are provided in Table 5.

**Table 5. Procedures, treatments, and characteristics of coronary artery disease**

	COHORT (N= 237)
<b>Median time from arrest to coronary angiography (IQR) – min</b>	135 (107-170)
<b>Median time of coronary angiography (IQR) – min</b>	19 (11-33)
<b>Catheterization access – no. (%)</b>	
• Radial	192 (81)
• Femoral	41 (17)
<b>Severity of coronary artery disease – no. (%)</b>	
• No significant disease	75 (32)
• One-vessel disease	159 (67)
• Two-vessel disease	60 (25)
• Three-vessel disease	54 (23)
<b>Culprit lesion identified – no. (%)</b>	115 (49)
<b>Revascularization treatment – no. (%)</b>	
• PCI performed	101 (43)
• CABG	1 (0,4)
• Pharmacologic or conservative treatment	59 (25)
<b>Median amount of contrast dye (IQR) – mL</b>	145 (52-120)

The median time from arrest to coronary angiography was similar in both groups: 135 minutes in STE-OHCA group and 130 min in NSTE-OHCA group ( $p=0,12$ ). Radial access was routinely chosen as a first line access in both groups ( $p=0,77$ ). The median time of CAG was longer in STE-OHCA group than in NSTE-OHCA group ( $p<0,01$ ). Culprit lesion was identified in 49% of all OHCA. However, we observed a significant difference between STE-OHCA group and NSTE-OHCA group. A culprit lesion was identified in 89 patients of STE-OHCA group (72%) and only in 24 patients of NSTE-OHCA group (21%) ( $p<0,001$ ). Bitruncular and tritrunicular lesions rate were not statistically different between groups.

The revascularization by PCI rate was 43% in the entire cohort (whereas it was 49% of patients with a culprit lesion identified). We observed that in STE-OHCA group, treatment of the identified culprit lesion by PCI was made as a first choice in 66% of patients vs 14% in the NSTE-OHCA group ( $p<0,001$ ). On the contrary, in the NSTE-OHCA group, medical treatment

was prioritized in 35% of patients vs 15% in the STE-OHCA group. Surgery revascularization by CABG was realized for one patient in STE-OHCA group. The amount of contrast dye was significantly higher in STE-OHCA than in NSTE-OHCA ( $p<0,001$ ), certainly due to a longer time of CAG and higher rate of revascularization by PCI (Table 6).

**Table 6. Procedures, treatments, and characteristics of coronary artery disease**

	STE-OHCA (N= 124)	NSTE-OHCA (N=113)	p-value
<b>Median time from arrest to coronary angiography (IQR) – min</b>	135 (110-174)	130 (100-161)	0,12
<b>Median time of coronary angiography (IQR) – min</b>	25 (14-39)	15 (10-20)	<b>&lt; 0,01</b>
<b>Catheterization access – no. (%)</b>			
• Radial	98 (79)	90 (80)	0,77
• Femoral	23 (19)	18 (16)	0,67
<b>Severity of coronary artery disease – no. (%)</b>			
• No significant disease	23 (19)	50 (44)	0,06
• One-vessel disease	39 (32)	22 (20)	0,10
• Two-vessel disease	32 (26)	22 (20)	0,54
• Three-vessel disease	29 (23)	15 (13)	0,30
<b>Culprit lesion identified – no. (%)</b>	89 (72)	24 (21)	<b>&lt; 0,001</b>
<b>Revascularization treatment – no. (%)</b>			
• PCI performed	82 (66)	16 (14)	<b>&lt; 0,001</b>
• CABG	1 (1)	0 (0)	1,00
• Pharmacologic or conservative treatment	18 (15)	39 (35)	<b>&lt; 0,001</b>
<b>Median amount of contrast dye (IQR) – mL</b>	92 (61-132)	63 (50-99)	<b>&lt; 0,001</b>

## ICU

Intensive care management were similar in the two groups with no statistically significant differences (Table 8). In average, 100 minutes were necessary to transfer patients from the cath lab to the ICU (the main ICU being in a different hospital at 8.6 km distance) for the STE-OHCA group and 90 minutes for the NSTE-OHCA group ( $p=0,49$ ).

**Table 7. Baseline characteristics at admission in ICU**

	COHORT (N= 237)
<b>Median time from cath lab to ICU transfer (IQR) – min</b>	100 (77-123)
<b>Median score range of Glasgow Coma Scale at admission in ICU (IQR)</b>	3 (3-3)
<b>Median blood pressure (IQR) – mmHg</b> <ul style="list-style-type: none"><li>• Systolic</li><li>• Diastolic</li><li>• PAM</li></ul>	121 (101-140) 71 (60-85) 87 (75-101)
<b>Inotropic support – no. (%)</b>	120 (51)
<b>Median temperature (IQR) – °Celsius</b>	35,4 (34,5-36,1)
<b>Median left ventricular ejection fraction (IQR) – %</b>	40 (30-50)
<b>Baseline laboratory values</b> <ul style="list-style-type: none"><li>• pH</li><li>• Median lactic acid (IQR) – mmol/liter</li><li>• Median partial pressure of O<sub>2</sub> (IQR) – kPa</li><li>• Median partial pressure of CO<sub>2</sub> (IQR) – kPa</li><li>• Median creatinine (IQR) – µmol/liter</li><li>• Median troponin ratio (IQR)</li><li>• Median hemoglobin (IQR) – (g/dl)</li></ul>	7,31 (7,23-7,37) 2,5 (1,5-4,2) 118 (83-193) 41 (38-46) 98 (81-124) 43 (10-119) 13,7 (12,4-14,9)
<b>Hypothermia protection – no. (%)</b>	118 (50)
<b>Pupillary reflex presence – no. (%)</b>	138 (58)

Median temperature at the arrival in ICU was 35,5° (STE-OHCA) and 35,3° (NSTE-OHCA group), and hypothermia protection was initiated in 47% in STE-OHCA group vs 52% in NSTE-OHCA group. The median length of ICU hospitalization, of mechanical ventilation or of inotropic support were similar and not statistically significantly different (Table 8).

**Table 8. Baseline characteristics at admission in ICU**

	STE-OHCA (N= 124)	NSTE-OHCA (N=113)	p-value
<b>Median time from cath lab to ICU transfer (IQR) – min</b>	100 (82-127)	90 (70-120)	0,49
<b>Median score range of Glasgow coma scale at admission in ICU (IQR)</b>	3 (3-3)	3 (3-3)	0,42
<b>Median blood pressure (IQR) – mmHg</b>			
• Systolic	121 (103-136)	121 (103-140)	0,59
• Diastolic	72 (64-85)	68 (60-84)	0,31
• PAM	89 (78-100)	87 (75-103)	0,96
<b>Inotropic support – no. (%)</b>	66 (53)	52 (46)	0,41
<b>Median temperature (°Celsius) (IQR)</b>	35,5 (34,6-36,2)	35,3 (34,4-36)	0,97
<b>Median left ventricular ejection fraction (IQR) – %</b>	40 (30-50)	45 (30-60)	0,35
<b>Baseline laboratory values</b>			
• pH	7,32 (7,25-7,37)	7,29 (7,20-7,36)	0,21
• Median lactic acid (IQR) – mmol/liter	2,4 (1,4-3,9)	2,7 (1,8-4,3)	0,32
• Median partial pressure of O <sub>2</sub> (IQR) – kPa	111 (82-165)	140 (93-227)	< 0,05
• Median partial pressure of CO <sub>2</sub> (IQR) – kPa	41 (37-47)	43 (38-46)	0,74
• Median creatinine (IQR) – μmol/liter	94 (78-114)	105 (90-134)	< 0,001
• Median troponin ratio (IQR)	79 (25-181)	14 (5-53)	< 0,001
• Median hemoglobin (IQR) – (g/dl)	13,6 (12,5-15,1)	13,8 (12,2-14,8)	0,22
<b>Hypothermia protection – no. (%)</b>	58 (47)	59 (52)	0,33
<b>Pupillary reflex presence – no. (%)</b>	71 (57)	66 (58)	0,45

## PRIMARY AND SECONDARY END POINTS

Mortality in ICU was higher in NSTE-OHCA (54%) than in STE-OHCA (42%) but didn't reach statistical significance. However, at 30 days, mortality was significantly higher in the NSTE-OHCA group than in the STE-OHCA group (57% vs 43% with p<0,05).

Our secondary efficacy end points: neurological deficit (Glasgow Coma Scale at the discharge of the ICU), length of stay in the ICU, length of mechanical ventilation, length of inotropic support were similar between groups. Biological criteria showed that STE-OHCA patients had a significant higher median troponin ratio (p<0,01), whereas median creatinine level were higher in NSTE-OHCA (p<0,05). Our secondary safety end points (severe bleeding, stroke, ventricular tachycardia, and acute kidney failure leading to renal-replacement therapy) were also similar between groups, with no statistical difference (Table 9). NSE levels were unfortunately not comparable due to missing data.

**Table 9. Clinical outcomes**

	STE-OHCA (N= 124)	NSTE-OHCA (N=113)	p-value
<b>Primary end point</b>			
• Death from any cause in ICU – no. (%)	52 (42)	61 (54)	0,098
• Death from any cause at 30 days – no. (%)	53 (43)	64 (57)	< 0,05
<b>Secondary efficacy end points</b>			
• Median length of ICU hospitalization (IQR) – days	4 (2-7)	4 (2-7)	0,80
• Median length of mechanical ventilation (IQR) – days	3 (2-6)	3 (1-6)	0,49
• Median length of inotropic support (IQR) – days	1 (0-1)	0 (0-1)	0,75
• Median score range of Glasgow Coma Scale at discharge in ICU (IQR)	9 (3-15)	8 (3-15)	< 0,55
<b>Biology</b>			
• Median creatinine peak (IQR) - µmol/L	96 (82-140)	120 (94-162)	<0,05
• Median troponin peak ratio (IQR)	187 (67-562)	42 (8-111)	<0,01
• Median NSE range (IQR) – ng/mL	33 (21-80)*	82 (28-236)*	
<b>Secondary safety end points – no. (%)</b>			
• Severe bleeding	13 (11)	8 (7)	0,48
• Stroke	2 (2)	5 (4)	0,16
• Ventricular tachycardia (VT)	13 (11)	7 (6)	0,25
• Acute kidney failure leading to renal replacement therapy	0 (0)	0 (0)	1,00

\* NSE (*more than 80% of missing data*)

## UNIVARIATE AND MULTIVARIATE SURVIVAL ANALYSIS

We first performed a univariate analysis in order to focus more on possible items able to predict mortality (Table 10). The univariate analysis showed that the presence of NSTE was associated with a 78% higher mortality risk (OR 1,78 [1,07-2,98], p=0,028).

Some cardiovascular risks increased the mortality risk such as the presence of diabetes mellitus with a 3 to 4 fold increase (OR 3,58 [1,75-7,32], p<0,001), hypertension that doubled the risk (OR 2,12 [1,27-3,56], p=0,005), age and BMI were also associated with a slightly higher risk of mortality (respectively OR 1,03 and 1,06 with p<0,05). Surprisingly, active smoking was not significantly associated with higher risk of mortality (OR 0,75 [0,43-1,28], p=0,29). We observed as well that a previous coronary artery disease was not associated with higher mortality neither (OR 0,97 [0,48-1,99], p=0,94), contrary to a previous peripheral artery disease (OR 4,09 [1,12-14,95], p=0,034). The presence of a shockable first monitored rhythm was significantly decreasing mortality by 83% (OR 0,17 [0,09-0,32], p<0,001), and so was the

identification of a culprit lesion at CAG (OR 0,55 [0,33-0,92], p=0,023). Transfer duration to the cath lab or to the ICU did not impact survival in our cohort.

In ICU, the main predictor factors of mortality were the necessity to use inotropic support, the absence of pupillary reflex, and elevated temperature at admission, whereas hypothermia protection measures did not seem to impact patients survival. Acidosis with pH<7,20 and lactic acid elevation were also associated with a higher rate of mortality. Length of ICU hospitalization was associated with a small reduction of mortality (OR 0,93 [0,89-0,98], p=0,005), whereas the length of mechanical ventilation had no significant impact (p=0,93).

We then performed a multivariate analysis by using some of the significant predictable factors from the univariate analysis (age, shockable first monitored rhythm, culprit lesion identified, use of inotropic support). Two factors remained significantly associated with higher mortality: age and the absence of a shockable first monitored rhythm.

**Table 10. Estimates of OR and 95% CI of predictors of mortality using linear logistic regression**

	OR	95% CI	p-value
<b>Univariate analysis</b>			
NSTE-OHCA	1,78	1,07-2,98	<b>0,028</b>
Age (years)	1,03	1,018-1,058	<b>&lt;0,001</b>
Male sex	0,84	0,47-1,52	0,57
BMI (kg/m <sup>2</sup> )	1,06	1,01-1,11	<b>0,015</b>
Diabetes mellitus	3,58	1,75-7,32	<b>&lt;0,001</b>
Hypertension	2,12	1,27-3,56	<b>0,005</b>
Smoking	0,75	0,43-1,28	0,29
Chronic kidney failure	0,68	0,11-4,13	0,68
Previous coronary artery disease	0,97	0,48-1,99	0,94
Previous peripheral artery disease	4,09	1,12-14,95	<b>0,034</b>
Shockable first monitored rhythm	0,17	0,09-0,32	<b>&lt;0,001</b>
Time from OHCA to coronary angiography (min)	0,99	0,98-1,00	0,30
Time from Cath Lab to ICU (min)	1,00	0,99-1,00	0,60
Culprit lesion identified	0,55	0,33-0,92	<b>0,023</b>
Use of inotropic support	1,99	1,19-3,35	<b>&lt;0,001</b>
Temperature at admission in ICU (°Celsius)	0,66	0,51-0,84	<b>0,001</b>
Hypothermia protection	0,65	0,39-1,09	0,10
Pupillary reflex presence	0,08	0,04-0,18	<b>&lt;0,001</b>

<b>Baseline laboratory values at admission in ICU</b>			
• pH :			
- pH<7,4	2,08	0,98-4,39	0,056
- pH <7,2	5,98	2,83-12,64	<b>&lt;0,001</b>
• lactic acid – mmol/liter	1,53	1,30-1,82	<b>&lt;0,001</b>
• median troponin ratio	1,00	0,99-1,00	0,08
• median creatinine – µmol/liter	1,02	1,01-1,03	<b>&lt;0,001</b>
<b>Length of ICU hospitalization – days</b>	0,93	0,89-0,98	<b>0,005</b>
<b>Length of mechanical ventilation - days</b>	0,99	0,95-1,05	0,93
<b>Multivariate analysis</b>			
<b>Death</b>			
• NSTE-OHCA	1,02	0,51-2,02	0,96
• Age	1,03	1,01-1,06	<b>&lt;0,001</b>
• Shockable first monitored rhythm	0,23	0,11-0,42	<b>&lt;0,001</b>
• Culprit lesion identified	0,55	0,28-1,09	0,09
• Inotrope support	1,61	0,90-2,87	0,11


## NORMAL CAG

We performed a subgroup analysis to study the proportion of normal CAG. Characteristics are reported in Table 12 in the Supplementary data. We observed that normal CAG was mainly observed in younger patients (with a median age at 59 year). There was a lower rate of previous coronary artery disease. The circumstances of cardiac arrest were not different, but there was a trend to a lower number of shockable rhythms in comparison of the rate in STE-OHCA and an equal rate in comparison with NSTE-OHCA group. The post resuscitation ECG showed a STE rate of 30% and a NSTE rate of 70% in this subgroup. No difference in mortality was noted compared to patients with abnormal CAG.

## NSTE-CULPRIT LESION-REVASCULARIZATION

In the NSTE-OHCA group, we also studied patients in whom a culprit lesion had been identified and subsequently revascularized. There were only 16 patients (14%) (Figure 2). These patients were older (72 vs 65 year old) and more frequently current smokers (50% vs 29%). The circumstances of cardiac arrest were the same, particularly as to the presence of a

shockable rhythm (63% versus 58%). NF and LF durations were similar. Coronary angiography revealed a majority of bitruncular lesions (63%), the majority with circumflex occlusion (50%). Data on ICU admission and hospitalization were comparable. Mortality at 30 days was lower, with a 69% survival rate versus a 43% survival rate in the other NSTE-OHCA patients.



**Figure 2. Repartition of culprit lesion in NSTE-OHCA (no. (%))**

## EVOLUTION BY YEAR

Results were summarized in Supplementary Data (Figure 3-4). Results by year during the last decade showed that number of patients who underwent an emergency CAG after resuscitated OHCA is decreasing, with a majority of STE on ECG, which is consistent with recent recommendations.

## Discussion

The aim of our study was to review our practice at University of Tours in the last 10 years regarding the management of OHCA with suspected cardiac cause and to define the place and timing of coronarography in these situations.

237 patients were included during the last decade, and our management of OHCA evolved along the years with the new recommendations based on randomized studies. Our cardiology center is the only center with a cath lab and extracorporeal circulation system of a 600 000 inhabitants area. Thus, it plays a major role in the management of OHCA. Our results are consistent with the published data, as our cohort includes young patients, mostly men, with high cardiovascular risk and are similar to the characteristics of randomized trials<sup>20-22</sup> (COACT, TOMAHAWK, EMERGE). Our mortality rate at 30 days is 49% in the cohort, 43% in STE-OHCA group and 57% in NSTE-OHCA group. These results are in keeping with the 50% mortality rate at 30 days observed in the TOMAHAWK<sup>21</sup> study, the 35% mortality rate observed at 90 days in the COACT study, and the 65% observed at 180 days in the EMERGE<sup>22</sup> study.

The analysis of our results by year shows a shift in our practice: less coronarography over the years for the same incidence of OHCA (with an exceptional decrease in 2020 and 2021, years of COVID worldwide pandemic). That may be explained by the release of new recommendations based on randomized trials favoring emergency CAG in patients with shockable heart rhythm and/or STE on ECG. Indeed, the latest studies and lately, the *Heyne and al* meta-analysis<sup>23</sup>, did not manage to prove a benefit of an immediate versus a delayed CAG in OHCA without ST segment elevation leading to new recommendations.

Our results are consistent with the release of these new recommendations as we observed since 2019 a clear decrease of immediate CAG in patients with NSTE-OHCA and an increase of immediate CAG in STE-OHCA, with almost exclusively immediate CAG in STE-OHCA patients since 2019. Actual recommendations are based on 3 parameters: medical history, shockable rhythm and post resuscitation ECG. Data regarding previous medical history and cardiac symptoms before cardiac arrest are often difficult to collect in the setting of an emergency intervention for OHCA in unconscious patients with witnesses that may have no knowledge of the patients when there is a witness. Our 10-year retrospective study was unable to reliably retrieve these data.

Our analysis of post resuscitation ECG revealed the following information: ECG post resuscitation showed mostly narrow QRS, with localized ischemia in a coronary territory, mostly anterior and inferior in STE-OHCA, and lateral territory in NSTE-OHCA. In the NSTE-OHCA group, the ECG study showed a significantly higher rate of bundle-branch block. "Ischemic" signs are more diffuse and more lateral, which may be explained by the presence of a bundle branch block (BBB) and its secondary repolarization trouble. Some studies show that the appearance of a BBB on post resuscitation ECG could be linked to non-specific secondary repolarization disorders due to CPR management (metabolic disorders post cardiac arrest, use of adrenaline...) which render the interpretation of these NSTE "ischemia sign" complicated<sup>26-30</sup>.

Coronary angiography revealed a culprit lesion in 72% of STE-OHCA, with revascularization of this lesion in 66% of cases, almost exclusively by angioplasty at the same time as the diagnostic coronary angiography, whereas only 21% of NSTE-OHCA had a culprit lesion (and only 14% were revascularized, the others were treated medically). Early revascularization has been proven beneficial in reducing mortality, particularly in the most severe situations, such as cardiogenic shock<sup>24,25</sup>. It probably explains the significant difference in mortality between the STE-OHCA and NSTE-OHCA groups in patients with similar severity at the admission to the ICU.

Moreover, the coronary angiography lesions showed a coronary lesion rate equivalent in terms of bitruncular or tritrunicular lesions in both groups (around 25% in STE-OHCA and 20% in NSTE-OHCA), but with more frequently chronic lesions incidentally discovered, since the rate of acute culprit lesions was only 21%. The chronic lesions rate in our study needs to be analyzed with the characteristics of the NSTE group in mind. These patients were older with a higher cardiovascular risk (significantly more comorbidities, especially more kidney failure with GFR < 30 mL/min). These patients had more frequently a previous history of coronary artery disease, which probably influenced the decision to undergo immediately coronary angiography, as they have a significantly higher rate of sudden death than in general population. In our retrospective study, we found a 21% rate of culprit lesion in NSTE-OHCA group, which was similar to the culprit lesion rate in TOMAHAWK (23%), in PROCRAT II<sup>12</sup> (29%) and in Spirito and al<sup>31</sup> (20%).

Our multivariate analysis showed that older age and absence of shockable first monitored rhythm were significantly associated with mortality rendering NSTE-OHCA no

longer significantly associated with mortality. Our results are consistent with the PROCRAT II study that showed that one of the predictive factors of favorable outcome in OHCA without STE was an initial shockable rhythm ( $p<0.001$ )<sup>12</sup> and that it was the sole independent indicator for PCI requirement in that population. The conclusion of PROCRAT II study was that CAG and PCI strategy in OHCA without STE was beneficial mostly for men older than 50 years old, with a shockable first rhythm monitored. Spirito *and al* found that chest pain or shockable first rhythm monitored were also two predictable factors associated in OHCA without STE to patients with acute coronary lesion. These observations strengthen the hypothesis that a first shockable monitored rhythm in NSTE-OHCA may help predict the presence of a culprit acute coronary lesion in the patients that is likely to benefit from an emergency CAG and subsequent PCI.

Our data confirm these findings. There was a higher and significant rate of shockable rhythm in the STE-OHCA group (77%), and a similar rate of shockable rhythm in the NSTE-OHCA group (58% vs 57% in the TOMAHAWK study). However, other studies found a weak correlation between the presence of a shockable rhythm and coronary occlusion (only 23%)<sup>32</sup>. In the Yannopoulos study, the culprit lesion rate rose to 64% only if there were more than 3 External Electric Shock (EECs)<sup>33</sup>. Besides, regarding the association between shockable first rhythm monitored and mortality in OHCA without STE, the COACT study who only included OHCA with a shockable rhythm did not prove any benefice on survival of an immediate versus delayed CAG in that population. We conclude that the presence of a shockable first rhythm monitored remains a debatable factor for the indication of emergency CAG in the NSTE-OHCA population.

To further assess the question of OHCA patients' prognosis, especially in NSTE-OHCA where survival was lower at 30 days, we studied the transfer delays between the initial OHCA location and the cath lab and from the cat lab to the ICU in our center. This because in cardiac arrest, neurological outcome is known to be linked to the early initiation of neuroprotection management. Indeed, neurological deficit remains a major preoccupation in intensive care management of OHCA patients, and this, whatever the final cause of cardiac arrest. Sooner is started neuroprotection management, better is the outcome with a lower neurological deficit<sup>34</sup>. Neuroprotection management is possible at every stage of the CPR process, from the very beginning of CPR to the hospitalization in ICU (maintaining cerebral circulation, regulation

of the  $\text{PO}_2/\text{PCO}_2$  and temperature in ICU...). During the last decade, hypothermia played a major role in neuroprotection at the beginning. However, its benefit versus normothermia<sup>35,36</sup> had been questioned and was progressively less used in ICU. In our study, even if low temperature at admission seemed to be associated with a better outcome (OR 0,66 [0,51-0,84], p=0,001) during the ICU hospitalization, hypothermia protection was not associated with a better survival (OR 0,65 [0,39-1,09], p=0,10). We did observe that trend in our study with a lower rate of hypothermia measures since 2015. Moreover, in our center, the cath lab and the medical ICU are in different areas of the city. We observed a median transfer time of 100 min in our cohort that results both from the distance and the needs to mobilize considerable health care resources to organize the medical transfer of ventilated patients that are sometimes unstable. This may have delayed the initiation of neuroprotection maneuvers. This delayed neuroprotection management may partly explain the increase of mortality in NSTE-OHCA group, even if in our study, time of transfer from cath lab to ICU was not a predictor factor of death (OR 1,00 [0,99-1,00], p=0,60).

Concerning our secondary end point criteria (Glasgow Coma Scale at the discharge of the ICU), length of stay in the ICU, length of mechanical ventilation, length of inotropic support and our secondary safety end points severe bleeding, stroke, ventricular tachycardia, and acute kidney failure leading to renal-replacement therapy, there were no statistical difference between STE-OHCA and NSTE-OHCA. If we compare the incidence of these events in our NSTE-OHCA cohort with the COACT and TOMAHAWK results, we had similar proportions of VT events (<10%), severe bleeding (5%) and stroke (4-5%). We did observe a much lower incidence of acute kidney failure leading to renal-replacement therapy (<1% versus 15% in TOMAHAWK), that maybe partly explained by short CAG procedures with low amounts of contrast dye injection. This relatively low severe bleeding rate is probably due to the predominance of radial access in our center over the last 20 years. The radial puncture is preferred for STE group without OHCA in general, as it has been showed that radial puncture reduced mortality<sup>37</sup>. One of our major discordances with these two studies is the mean GSC Scale at discharge of ICU. Published studies report a mean of 15, whereas we observed a median GSC in both groups around 8-9 which could be explained by the inclusion of patients pronounced deceased at the discharge of ICU.

Finally, our data in NSTE-OHCA group seem to support the findings of randomized studies (COACT, TOMAHAWK, EMERGE, DISCO) that immediate coronary angiography did not

prove a benefit in overall mortality. We stepped our study further by analyzing data from patients with normal coronary angiography. Indeed, if the cause of cardiac arrest is well identified as a non-ischemic cause, the futility of coronary angiography seems obvious. However, as previously discussed, the clinical history is often difficult to collect, as well as a normal ECG does not predict a 100% rate of normal CAG<sup>38</sup>. Recent scores tried to predict acute coronary lesion post OHCA (for example, ASC2 score based on the presence of angina, congestive heart failure, a shockable arrest rhythm or the presence of ST elevation in two contiguous leads), but the results were unfortunately no reliable without ST segment elevation<sup>39</sup>. Patients with a normal CAG were younger patients, aged 59, with an equivalent sex ratio and cardiovascular risk. Regarding the circumstances of cardiac arrest, there was no significant difference except for shockable rhythm. We observed less shockable rhythms in patients with normal CAG than in patient with STE, but equal proportion of shockable rhythm in comparison with NSTE . Post-resuscitation ECG showed a STE rate of 30%, resulting in a false positive in one third of cases, confirming the limited reliability of ECG alone.

The next question to assess in out-of-hospital cardiac arrest is to identify more precisely criteria in NSTE-OHCA patients, helping us to select with a high specificity and sensibility patients with acute coronary syndrome and culprit lesion, for whom coronary angiography and early revascularization may then be beneficial. The data from our study should be treated with caution due to the small number of patients involved, but we have noted an improvement in survival of almost 70%.

However, our study has some limits that need to be acknowledged. It is a retrospective study that involves missing data, especially on neurologic evaluation in ICU (NSE, pupillary reflex, time to hypothermia...). We had to use the Glasgow Coma Scale at the discharge of ICU, despite its imprecision, and the fact that it was not validated for neurological evaluation after OHCA. CPC scale used in most studies<sup>20,21</sup> was not retrospectively available for our cohort. Post resuscitation ECG could not be all re-analyzed as some of them were not scanned in patient's file. The investigators relied on ECG analysis reported in patients' medical files. It could result in some misinterpretation in ECG analysis, even if most ECG analysis retrieved in the electronic files were performed by experienced cardiologists.

In conclusion, there is still a long way to go to precisely define the subgroup of patients in which immediate CAG after OHCA without STE, would be benefic and with a good neurological predictable outcome, in order to be harmless and avoid futile interventions<sup>40,41</sup>.

By using a combined score, *Pareek and al*<sup>42</sup> showed that immediate CAG is associated with improved neurological outcome in selected patients with OHCA with favorable prediction of neurologic recovery (MIRA-CLE2 score 0-3), cardiogenic shock (SCAI grades B-E), or STEMI on arrival. Unfortunately, immediate CAG, good neurological outcome and NSTEMI were not significantly associated. Future trials are coming in order to further answer the question of the optimal treatment and timing of CAG in NSTE-OHCA<sup>43</sup>.

## Conclusion

Management of OHCA patients with cardiac cause (ST elevation or No ST elevation) in our center during the last decade is consistent with the recent recommendations. Our results confirm the need for coronary angiography in patients with STE and the lack of benefit of emergency coronary angiography in patients without STE on post ECG resuscitation. Future work should focus on identifying no-STE patients with acute coronary lesions that may benefit from emergency CAG and subsequent revascularization.

## Bibliography

1. CENTRE D'EXPERTISE MORT SUBITE CEMS-Paris. <https://www.cems-paris.fr/>.
2. Gräsner, J.-T., Wnent, J., Herlitz, J., Perkins, G.D., Lefering, R., Tjelmeland, I., Koster, R.W., Masterson, S., Rossell-Ortiz, F., Maurer, H., et al. (2020). Survival after out-of-hospital cardiac arrest in Europe - Results of the EuReCa TWO study. *Resuscitation* 148, 218–226. 10.1016/j.resuscitation.2019.12.042.
3. American Heart Association | To be a relentless force for a world of longer, healthier lives [www.heart.org](http://www.heart.org/en/). <https://www.heart.org/en/>.
4. Yan, S., Gan, Y., Jiang, N., Wang, R., Chen, Y., Luo, Z., Zong, Q., Chen, S., and Lv, C. (2020). The global survival rate among adult out-of-hospital cardiac arrest patients who received cardiopulmonary resuscitation: a systematic review and meta-analysis. *Crit. Care Lond. Engl.* 24, 61. 10.1186/s13054-020-2773-2.
5. Spaulding, C.M., Joly, L.-M., Rosenberg, A., Monchi, M., Weber, S.N., Dhainaut, J.-F.A., and Carli, P. (1997). Immediate Coronary Angiography in Survivors of Out-of-Hospital Cardiac Arrest. *N. Engl. J. Med.* 336, 1629–1633. 10.1056/NEJM199706053362302.
6. Geri, G., Passouant, O., Dumas, F., Bougouin, W., Champigneulle, B., Arnaout, M., Chelly, J., Chiche, J.-D., Varenne, O., Guillemet, L., et al. (2017). Etiological diagnoses of out-of-hospital cardiac arrest survivors admitted to the intensive care unit: Insights from a French registry. *Resuscitation* 117, 66–72. 10.1016/j.resuscitation.2017.06.006.
7. Hochman, J.S., Sleeper, L.A., Webb, J.G., Sanborn, T.A., White, H.D., Talley, J.D., Buller, C.E., Jacobs, A.K., Slater, J.N., Col, J., et al. (1999). Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. *N. Engl. J. Med.* 341, 625–634. 10.1056/NEJM199908263410901.
8. Nikolaou, N.I., Welsford, M., Beygui, F., Bossaert, L., Ghaemmaghami, C., Nonogi, H., O'Connor, R.E., Pichel, D.R., Scott, T., Walters, D.L., et al. (2015). Part 5: Acute coronary syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. *Resuscitation* 95, e121–e146. 10.1016/j.resuscitation.2015.07.043.
9. Hollenbeck, R.D., McPherson, J.A., Mooney, M.R., Unger, B.T., Patel, N.C., McMullan, P.W., Hsu, C.-H., Seder, D.B., and Kern, K.B. (2014). Early cardiac catheterization is associated with improved survival in comatose survivors of cardiac arrest without STEMI. *Resuscitation* 85, 88–95. 10.1016/j.resuscitation.2013.07.027.
10. Staudacher, I.I., Uil, C. den, Jewbali, L., Zandvoort, L. van, Zijlstra, F., Mieghem, N.V., Boersma, E., and Daemen, J. (2018). Timing of coronary angiography in survivors of out-of-hospital cardiac arrest without obvious extracardiac causes. *Resuscitation* 123, 98–104. 10.1016/j.resuscitation.2017.11.046.
11. Dumas, F., Cariou, A., Manzo-Silberman, S., Grimaldi, D., Vivien, B., Rosencher, J., Empana, J.-P., Carli, P., Mira, J.-P., Jouven, X., et al. (2010). Immediate Percutaneous Coronary Intervention Is Associated With Better Survival After Out-of-Hospital Cardiac Arrest. *Circ. Cardiovasc. Interv.* 3, 200–207. 10.1161/CIRCINTERVENTIONS.109.913665.
12. Dumas, F., Bougouin, W., Geri, G., Lamhaut, L., Rosencher, J., Pène, F., Chiche, J.-D., Varenne, O., Carli, P., Jouven, X., et al. (2016). Emergency Percutaneous Coronary Intervention in Post–Cardiac

Arrest Patients Without ST-Segment Elevation Pattern: Insights From the PROCAT II Registry. *JACC Cardiovasc. Interv.* 9, 1011–1018. 10.1016/j.jcin.2016.02.001.

13. Nolan, J.P., Sandroni, C., Böttiger, B.W., Cariou, A., Cronberg, T., Friberg, H., Genbrugge, C., Haywood, K., Lilja, G., Moulaert, V.R.M., et al. (2021). European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2021: post-resuscitation care. *Intensive Care Med.* 47, 369–421. 10.1007/s00134-021-06368-4.
14. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction 10.1161/CIR.0b013e3182742cf6.
15. Ibanez, B., James, S., Agewall, S., Antunes, M.J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A.L.P., Crea, F., Goudevenos, J.A., Halvorsen, S., et al. (2018). 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur. Heart J.* 39, 119–177. 10.1093/eurheartj/ehx393.
16. Collet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D.L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021). 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur. Heart J.* 42, 1289–1367. 10.1093/eurheartj/ehaa575.
17. Elfwén, L., Lagedal, R., Nordberg, P., James, S., Oldgren, J., Böhm, F., Lundgren, P., Rylander, C., Linden, J. van der, Hollenberg, J., et al. (2019). Direct or subacute coronary angiography in out-of-hospital cardiac arrest (DISCO)—An initial pilot-study of a randomized clinical trial. *Resuscitation* 139, 253–261. 10.1016/j.resuscitation.2019.04.027.
18. Kern, K.B., Radsel, P., Jentzer, J.C., Seder, D.B., Lee, K.S., Lotun, K., Janardhanan, R., Stub, D., Hsu, C.-H., and Noc, M. (2020). Randomized Pilot Clinical Trial of Early Coronary Angiography Versus No Early Coronary Angiography After Cardiac Arrest Without ST-Segment Elevation. *Circulation* 142, 2002–2012. 10.1161/CIRCULATIONAHA.120.049569.
19. Viana-Tejedor, A., Andrea-Riba, R., Scardino, C., Ariza-Solé, A., Bañeras, J., García-García, C., Jiménez Mena, M., Vila, M., Martínez-Sellés, M., Pastor, G., et al. (2023). Coronary angiography in patients without ST-segment elevation following out-of-hospital cardiac arrest. COUPE clinical trial. *Rev. Esp. Cardiol. Engl. Ed.* 76, 94–102. 10.1016/j.rec.2022.05.013.
20. Lemkes, J.S., Janssens, G.N., van der Hoeven, N.W., Jewbali, L.S.D., Dubois, E.A., Meuwissen, M., Rijpstra, T.A., Bosker, H.A., Blans, M.J., Bleeker, G.B., et al. (2019). Coronary Angiography after Cardiac Arrest without ST-Segment Elevation. *N. Engl. J. Med.* 380, 1397–1407. 10.1056/NEJMoa1816897.
21. Desch, S., Freund, A., Akin, I., Behnes, M., Preusch, M.R., Zelniker, T.A., Skurk, C., Landmesser, U., Graf, T., Eitel, I., et al. (2021). Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation. *N. Engl. J. Med.* 385, 2544–2553. 10.1056/NEJMoa2101909.
22. Hauw-Berlemont, C., Lamhaut, L., Diehl, J.-L., Andreotti, C., Varenne, O., Leroux, P., Lascarrou, J.-B., Guerin, P., Loeb, T., Roupie, E., et al. (2022). Emergency vs Delayed Coronary Angiogram in Survivors of Out-of-Hospital Cardiac Arrest: Results of the Randomized, Multicentric EMERGE Trial. *JAMA Cardiol.* 7, 700–707. 10.1001/jamacardio.2022.1416.
23. Heyne, S., Macherey, S., Meertens, M.M., Braumann, S., Nießen, F.S., Tichelbäcker, T., Baldus, S., Adler, C., and Lee, S. (2023). Coronary angiography after cardiac arrest without ST-elevation myocardial infarction: a network meta-analysis. *Eur. Heart J.* 44, 1040–1054. 10.1093/eurheartj/ehac611.

24. Hochman, J.S., Sleeper, L.A., Webb, J.G., Sanborn, T.A., White, H.D., Talley, J.D., Buller, C.E., Jacobs, A.K., Slater, J.N., Col, J., et al. (1999). Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock. *N. Engl. J. Med.* *341*, 625–634. 10.1056/NEJM199908263410901.
25. Thiele, H., Akin, I., Sandri, M., Fuernau, G., de Waha, S., Meyer-Saraei, R., Nordbeck, P., Geisler, T., Landmesser, U., Skurk, C., et al. (2017). PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. *N. Engl. J. Med.* *377*, 2419–2432. 10.1056/NEJMoa1710261.
26. Diercks, D.B., Shumaik, G.M., Harrigan, R.A., Brady, W.J., and Chan, T.C. (2004). Electrocardiographic manifestations: electrolyte abnormalities. *J. Emerg. Med.* *27*, 153–160. 10.1016/j.jemermed.2004.04.006.
27. Sideris, G., Voicu, S., Dillinger, J.G., Stratiev, V., Logeart, D., Broche, C., Vivien, B., Brun, P.-Y., Deye, N., Capan, D., et al. (2011). Value of post-resuscitation electrocardiogram in the diagnosis of acute myocardial infarction in out-of-hospital cardiac arrest patients. *Resuscitation* *82*, 1148–1153. 10.1016/j.resuscitation.2011.04.023.
28. Salam, I., Hassager, C., Thomsen, J.H., Langkjær, S., Søholm, H., Bro-Jeppesen, J., Bang, L., Holmvang, L., Erlinge, D., Wanscher, M., et al. (2016). Editor's Choice-Is the pre-hospital ECG after out-of-hospital cardiac arrest accurate for the diagnosis of ST-elevation myocardial infarction? *Eur. Heart J. Acute Cardiovasc. Care* *5*, 317–326. 10.1177/2048872615585519.
29. Zanuttini, D., Armellini, I., Nucifora, G., Grillo, M.T., Morocutti, G., Carchietti, E., Trillò, G., Spedicato, L., Bernardi, G., and Proclemer, A. (2013). Predictive value of electrocardiogram in diagnosing acute coronary artery lesions among patients with out-of-hospital-cardiac-arrest. *Resuscitation* *84*, 1250–1254. 10.1016/j.resuscitation.2013.04.023.
30. Sharma, A., Miranda, D.F., Rodin, H., Bart, B.A., Smith, S.W., and Shroff, G.R. (2020). Do not disregard the initial 12 lead ECG after out-of-hospital cardiac arrest: It predicts angiographic culprit despite metabolic abnormalities. *Resusc. Plus* *4*, 100032. 10.1016/j.resplu.2020.100032.
31. Spirito, A., Vainsora, L., Papadis, A., Iacovelli, F., Sardu, C., Selberg, A., Bär, S., Kavaliauskaitė, R., Temperli, F., Asatryan, B., et al. (2023). Acute Coronary Occlusion in Patients With Non-ST-Segment Elevation Out-of-Hospital Cardiac Arrest. *J. Am. Coll. Cardiol.* *81*, 446–456. 10.1016/j.jacc.2022.10.039.
32. Kern, K.B., Lotun, K., Patel, N., Mooney, M.R., Hollenbeck, R.D., McPherson, J.A., McMullan, P.W., Unger, B., Hsu, C.-H., Seder, D.B., et al. (2015). Outcomes of Comatose Cardiac Arrest Survivors With and Without ST-Segment Elevation Myocardial Infarction: Importance of Coronary Angiography. *JACC Cardiovasc. Interv.* *8*, 1031–1040. 10.1016/j.jcin.2015.02.021.
33. Yannopoulos, D., Bartos, J.A., Aufderheide, T.P., Callaway, C.W., Deo, R., Garcia, S., Halperin, H.R., Kern, K.B., Kudenchuk, P.J., Neumar, R.W., et al. (2019). The Evolving Role of the Cardiac Catheterization Laboratory in the Management of Patients With Out-of-Hospital Cardiac Arrest: A Scientific Statement From the American Heart Association. *Circulation* *139*, e530–e552. 10.1161/CIR.0000000000000630.
34. Chalkias, A., and Xanthos, T. (2012). Post-cardiac arrest brain injury: Pathophysiology and treatment. *J. Neurol. Sci.* *315*, 1–8. 10.1016/j.jns.2011.12.007.
35. Dankiewicz, J., Cronberg, T., Lilja, G., Jakobsen, J.C., Levin, H., Ullén, S., Rylander, C., Wise, M.P., Oddo, M., Cariou, A., et al. (2021). Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest. *N. Engl. J. Med.* *384*, 2283–2294. 10.1056/NEJMoa2100591.

36. Holgersson, J., Meyer, M.A.S., Dankiewicz, J., Lilja, G., Ullén, S., Hassager, C., Cronberg, T., Wise, M.P., Bělohlávek, J., Hovdenes, J., et al. (2022). Hypothermic versus Normothermic Temperature Control after Cardiac Arrest. *NEJM Evid.* 1, EVIDoa2200137. 10.1056/EVIDoa2200137.
37. Valgimigli, M., Frigoli, E., Leonardi, S., Vranckx, P., Rothenbühler, M., Tebaldi, M., Varbella, F., Calabro, P., Garducci, S., Rubartelli, P., et al. (2018). Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. *Lancet Lond. Engl.* 392, 835–848. 10.1016/S0140-6736(18)31714-8.
38. Stær-Jensen, H., Nakstad, E.R., Fossum, E., Mangschau, A., Eritsland, J., Drægni, T., Jacobsen, D., Sunde, K., and Andersen, G.Ø. (2015). Post-Resuscitation ECG for Selection of Patients for Immediate Coronary Angiography in Out-of-Hospital Cardiac Arrest. *Circ. Cardiovasc. Interv.* 8, e002784. 10.1161/CIRCINTERVENTIONS.115.002784.
39. Matthew Kelham, Timothy A. Jones, Krishnaraj Rathod, Oliver Guttmann, Alastair Proudfoot, Andrew Wragg, Andreas Baumbach, Ajay Jain, Roshan Weerackody, Anthony Mathur, Daniel Jones. VALIDATION OF THE ACS2 SCORE FOR PREDICTING THE PRESENCE OF AN ACUTE CORONARY LESION IN PATIENTS FOLLOWING OUT OF HOSPITAL CARDIAC ARREST, Barts Heart Centre; Barts Health; Cardiac Research Centre, St Bartholomew's Hospital, London 10.1136/heartjnl-2019-BCS.148
40. Pham, V., Laghlam, D., Varenne, O., Dumas, F., Cariou, A., and Picard, F. (2021). Performance of OHCA, NULL-PLEASE and CAHP scores to predict survival in Out-of-Hospital Cardiac Arrest due to acute coronary syndrome. *Resuscitation* 166, 31–37. 10.1016/j.resuscitation.2021.07.011.
41. Spaulding, C., and Sideris, G. (2022). Immediate Coronary Angiogram in Out-of-Hospital Cardiac Arrest. *JACC Cardiovasc. Interv.* 15, 1085–1086. 10.1016/j.jcin.2022.04.009.
42. Pareek, N., Beckley-Hoelscher, N., Kanyal, R., Cannata, A., Kordis, P., Sunderland, N., Kirresh, A., Nevett, J., Fothergill, R., Webb, I., et al. (2022). MIRACLE2 Score and SCAI Grade to Identify Patients With Out-of-Hospital Cardiac Arrest for Immediate Coronary Angiography. *JACC Cardiovasc. Interv.* 15, 1074–1084. 10.1016/j.jcin.2022.03.035.
43. Wa, M.E.L.K., Silva, K.D., Pareek, N., and Perera, D. (2021). Coronary Revascularization and Out-of-hospital Cardiac Arrest: Past, Present and Future. *Heart Int.* 15, 94–102. 10.17925/HI.2021.15.2.94.

## Supplementary data

**Table 11. Comparison of daily medical treatment of the patients**

	STE-OHCA (N= 124)	NSTE-OHCA (N=113)	p-value
<b>Aspirin – no. (%)</b>	17 (14)	27 (24)	<0,05
<b>P2Y12 – no. (%)</b>	7 (6)	14 (12)	0,110
<b>Vitamin K antagonist (VKA) – no. (%)</b>	6 (5)	14 (12)	0,063
<b>Direct oral anticoagulant (DOAC) – no. (%)</b>	3 (2)	6 (5)	0,316
<b>Renin-angiotensin system (RAS) inhibitors – no. (%)</b>	29 (23)	48 (42)	<0,01
<b>Beta-blockers – no. (%)</b>	27 (22)	38 (34)	<0,05
<b>Metformin – no. (%)</b>	9 (7)	13 (12)	0,367

**Table 12. Summary of all the different groups and subgroups**

	COHORT (N= 237)	STE-OHCA (N= 124)	NSTE-OHCA (N=113)	NORMAL CAG (N= 74)	NSTE-OHCA with revascularized culprit lesion (N=16)
<b><u>Characteristics of the patients</u></b>					
<b>Median age (IQR) – year</b>	63 (51-71)	58 (50-69)	65 (55-76)	59 (45-69)	72 (62-81)
<b>Male sex – no. (%)</b>	180 (76)	94 (76)	83 (73)	49 (66)	14 (88)
<b>Median BMI (IQR) – kg/m<sup>2</sup></b>	27 (24-31)	27 (24-31)	27 (23-30)	25 (22-31)	28 (25-30)
<b>Cardiovascular risk – no. (%)</b> <ul style="list-style-type: none"><li>• Diabetes mellitus</li><li>• Hypertension</li><li>• Current smoker</li><li>• Dyslipidemia</li></ul>	45 (19) 114 (48) 79 (33) 76 (32)	18 (15) 55 (45) 45 (37) 33 (27)	26 (2) 58 (51) 33 (29) 42 (37)	16 (22) 29 (39) 22 (30) 18 (24)	2 (13) 9 (56) 8 (50) 7 (44)
<b>Previous coronary artery disease – no. (%)</b>	35 (15)	12 (10)	23 (20)	2 (3)	4 (25)
<b>Previous peripheral artery disease – no. (%)</b>	14 (6)	5 (4)	9 (8)	4 (5)	1 (6)
<b>Previous PCI – no. (%)</b>	26 (11)	8 (7)	18 (16)	2 (3)	4 (25)
<b>Previous CABG – no. (%)</b>	7 (3)	2 (2)	5 (4)	0 (0)	0 (0)
<b>Previous stroke – no. (%)</b>	9 (4)	7 (6)	2 (2)	0 (0)	1 (6)


<b>Previous heart surgery – no. (%)</b>	8 (3)	4 (3)	4 (4)	3 (4)	1 (6)
<b>Chronic kidney failure – no. (%)</b>	5 (2)	0 (0)	5 (4)	1 (1)	1 (6)
<b>Chronic respiratory failure – no. (%)</b>	1 (0,4)	0 (0)	1 (1)	1 (1)	0 (0)
<b>Daily medical treatment of the patients</b>					
<b>Aspirin – no. (%)</b>	45 (19)	17 (14)	27 (24)	11 (15)	2 (13)
<b>P2Y12 – no. (%)</b>	21 (9)	7 (6)	14 (12)	2 (3)	3 (19)
<b>Vitamin K antagonist (VKA) – no. (%)</b>	20 (8)	6 (5)	14 (12)	9 (12)	2 (13)
<b>Direct oral anticoagulant (DOAC) – no. (%)</b>	9 (4)	3 (2)	6 (5)	3 (4)	2 (13)
<b>Renin-angiotensin system (RAS) inhibitors – no. (%)</b>	78 (33)	29 (23)	48 (42)	21 (28)	8 (50)
<b>Beta-blockers – no. (%)</b>	66 (28)	27 (22)	38 (34)	22 (30)	3 (19)
<b>Metformin – no. (%)</b>	22 (9)	9 (7)	13 (12)	8 (11)	1 (6)
<b>Cardiac arrest circumstances</b>					
<b>Arrest witnessed – no. (%)</b>	200 (84)	104 (84)	92 (81)	59 (80)	14 (88)
<b>Bystander CPR – no. (%)</b>	174 (73)	95 (77)	75 (66)	51 (69)	13 (81)
<b>Shockable first monitored rhythm – no. (%)</b>	163 (69)	95 (77)	65 (58)	43 (58)	10 (63)
<b>Median time from</b>	5 (1-10)	3 (0-5)	5 (1-10)	5 (1-10)	1 (0-7)

<ul style="list-style-type: none"> <li>arrest to basic life support (<b>No Flow</b>) (IQR) – min</li> <li>arrest to return of spontaneous circulation (<b>Low Flow</b>) (IQR) – min</li> </ul>	20 (13-27)	20 (12-28)	20 (14-30)	20 (12-25)	20 (15-34)
<b><u>Procedures, treatments, and characteristics of coronary artery disease</u></b>					
<b>Median time from arrest to coronary angiography (IQR) – min</b>	135 (107-170)	135 (110-174)	130 (100-161)	130 (100-153)	121 (91-152)
<b>Median time of coronary angiography (IQR) – min</b>	19 (11-33)	25 (14-39)	15 (10-20)	12 (9-18)	31 (46)
<b>Catheterization access – no. (%)</b>					
• Radial	192 (81)	98 (79)	90 (80)	60 (81)	15 (94)
• Femoral	41 (17)	23 (19)	18 (16)	13 (18)	1 (6)
<b>Severity of coronary artery disease – no. (%)</b>					
• No significant disease	75 (32)	23 (19)	50 (44)	74 (100)	0 (0)
• One-vessel disease	159 (67)	39 (32)	22 (20)	/	4 (25)
• Two-vessel disease	60 (25)	32 (26)	22 (20)	/	10 (63)
• Three-vessel disease	54 (23)	29 (23)	15 (13)	/	2 (13)
<b>Culprit lesion identified – no. (%)</b>	115 (49)	89 (72)	24 (21)	/	16 (100)
<b>Revascularization treatment – no. (%)</b>					
• PCI performed	101 (43)	82 (66)	16 (14)	/	16 (100)
• CABG	1 (0,4)	1 (1)	0 (0)	/	0 (0)
• Pharmacologic or conservative treatment	59 (25)	18 (15)	39 (35)	/	0 (0)
<b>Median amount of contrast dye (IQR) – mL</b>	145 (52-120)	92 (61-132)	63 (50-99)	52 (41-66)	127 (112-164)


<u>Baseline characteristics at admission in ICU</u>					
<b>Median time from cath lab to ICU transfer (IQR) - min</b>	100 (77-123)	100 (82-127)	90 (70-120)	96 (75-120)	90 (67-115)
<b>Median score range of Glasgow Coma Scale at admission in ICU (IQR)</b>	3 (3-3)	3 (3-3)	3 (3-3)	3 (3-3)	3 (3-3)
<b>Median blood pressure (IQR) – mmHg</b>					
• Systolic	121 (101-140)	121 (103-136)	121 (103-140)	118 (99-130)	132 (117-149)
• Diastolic	71 (60-85)	72 (64-85)	68 (60-84)	67 (59-80)	67 (60-77)
• PAM	87 (75-101)	89 (78-100)	87 (75-103)	83 (71-97)	86 (83-102)
<b>Inotropic support – no. (%)</b>	120 (51)	66 (53)	52 (46)	38 (50)	6 (38)
<b>Median temperature (IQR) – °Celsius</b>	35,4 (34,5-36,1)	35,5 (34,6-36,2)	35,3 (34,4-36)	35,6 (34,5-36,2)	35,2 (34,7-35,8)
<b>Median left ventricular ejection fraction (IQR) - %</b>	40 (30-50)	40 (30-50)	45 (30-60)	45 (30-60)	45 (40-50)
<b>Baseline laboratory values</b>					
• pH	7,31 (7,23-7,37)	7,32 (7,25-7,37)	7,29 (7,20-7,36)	7,29 (7,21-7,37)	7,33 (7,21-7,36)
• Median lactic acid (IQR) – mmol/liter	2,5 (1,5-4,2)	2,4 (1,4-3,9)	2,7 (1,8-4,3)	2,7 (1,5-4,9)	2 (1,8-2,4)
• Median partial pressure of O <sub>2</sub> (IQR) – kPa	118 (83-193)	111 (82-165)	140 (93-227)	120 (87-196)	42 (40-46)
• Median partial pressure of CO <sub>2</sub> (IQR) – kPa	41 (38-46)	41 (37-47)	43 (38-46)	41 (37-46)	23 (21-36)
• Median creatinine (IQR) – µmol/liter	98 (81-124)	94 (78-114)	105 (90-134)	103 (82-135)	109 (96-128)
• Median troponin ratio (IQR)	43 (10-119)	79 (25-181)	14 (5-53)	10 (4-47)	19 (10-78)
• Median hemoglobin (IQR) – (g/dl)	13,7 (12,4-14,9)	13,6 (12,5-15,1)	13,8 (12,2-14,8)	13,5 (12,2-14,7)	13,6 (12,8-14,3)
<b>Hypothermia protection – no. (%)</b>	118 (50)	58 (47)	59 (52)	35 (47)	8 (50)
<b>Pupillary reflex presence – no. (%)</b>	138 (58)	71 (57)	66 (58)	38 (51)	13 (81)

<u>Clinical outcomes</u>					
<b>Primary end point</b> <ul style="list-style-type: none"> <li>Death from any cause in ICU – no. (%)</li> <li>Death from any cause at 30 days – no. (%)</li> </ul>	112 (47) 117 (49)	52 (42) 53 (43)	61 (54) 64 (57)	41 (55) 43 (58)	5 (31) 5 (31)
<b>Secondary efficacy end points</b> <ul style="list-style-type: none"> <li>Median length of ICU hospitalization (IQR) – days</li> <li>Median length of mechanical ventilation (IQR) – days</li> <li>Median length of inotropic support (IQR) – days</li> <li>Median score range of Glasgow Coma Scale at discharge in ICU (IQR)</li> </ul>	4 (2-7) 3 (1-6)	4 (2-7) 3 (2-6)	4 (2-7) 3 (1-6)	4 (2-7) 3 (2-5)	7 (2-15) 5 (2-8)
	1 (0-1) 6 (3-15)	1 (0-1) 9 (3-15)	0 (0-1) 8 (3-15)	1 (0-1) 3 (3-15)	0 (0-1) 14 (3-14)
<b>Biology</b> <ul style="list-style-type: none"> <li>Median creatinine peak (IQR) - µmol/L</li> <li>Median troponin peak ratio (IQR)</li> <li>Median NSE range (IQR) – ng/mL</li> </ul>	104 (83-150) 89 (22-297) 40 (23-161)*	96 (82-140) 187 (67-562) 33 (21-80)*	120 (94-162) 42 (8-111) 82 (28-236)*	102 (82-135) 19 (3-71) 40 (23-161)*	113 (101-192) 19 (3-71) 27 (22-28)*
<b>Secondary safety end points – no. (%)</b> <ul style="list-style-type: none"> <li>Severe bleeding</li> <li>Stroke</li> <li>Ventricular tachycardia</li> <li>Acute kidney failure leading to renal replacement therapy</li> </ul>	21 (9) 8 (3) 21 (9) 0 (0)	13 (11) 2 (2) 13 (11) 0 (0)	8 (7) 5 (4) 7 (6) 0 (0)	8 (11) 3 (4) 3 (4) 0 (0)	2 (12) 2 (12) 2 (12) 0 (0)







\*NSE (*more than > 80% of missing data*)




**Figure 3. Number of OHCA per year in our center from 2012 to 2022**




**Figure 4. Evolution during the years of percentage of STE-OHCA, NSTE-OHCA and culprit lesion**



**Figure 5. Localization of ischemia on ECG in our cohort and STE and NSTE-OHCA subgroups from 2012 to 2022**



**Figure 6. Evolution of catheterization access from 2012 to 2022**




Time to delayed angiography specified as median.

<sup>a</sup>The primary outcome in COACT was survival at 90 days, the hazard ratio for death is provided to allow comparison between trials. <sup>b</sup>Complete screening logs were not maintained for either trial. The recruitment rate was calculated from the screening samples and based on the number of patients that were eligible for the trial after all inclusion (including informed consent for COACT) and exclusion criteria were applied.

h = hours; HR = hazard ratio; IQR = interquartile range; NR = not recorded; OHCA = out-of-hospital cardiac arrest; VF = ventricular fibrillation; VT = ventricular tachycardia.

**Figure 7. Comparison of COACT and TOMAHWAK trials issued from Wa and al<sup>43</sup>**




Pareek N, et al. J Am Coll Cardiol Intv. 2022;15(10):1074-1084.

CAG = coronary angiography; LBBB = left bundle branch block; SCAI = Society for Cardiovascular Angiography and Interventions; STEMI = ST-segment elevation myocardial infarction.

**Figure 8. Results of the MIRACLE<sub>2</sub> Score and SCAI Grade to Identify Patients With Out-of-Hospital Cardiac Arrest for Immediate Coronary Angiography<sup>42</sup>**

Vu, le Directeur de Thèse Pr Denis Angoulvant

A handwritten signature in black ink, appearing to read "D. Angoulvant". It is written in a cursive style with a horizontal line through it.

Vu, le Doyen

De la Faculté de Médecine de Tours,

## LANDWERLIN Charlène

58 pages – 12 tableaux – 8 figures

### **Résumé :**

L'infarctus du myocarde est une des principales causes d'arrêt cardiaque extrahospitalier (ACR-EH). Cependant, la place de la coronarographie en urgence reste incertaine dans le cas des ACR-EH sans sus-décalage du segment ST. Ni les dernières recommandations de l'ESC ou de l'ACC/AHA, ni les essais randomisés (COACT, TOMAHAWK, EMERGE) n'ont réussi à définir clairement le délai et le bénéfice de la coronarographie en urgence sur la mortalité dans ce sous-groupe d'ACR-EH.

Notre étude rétrospective réalisée au CHU de Tours, de janvier 2012 à décembre 2022, étudie l'impact clinique de la réalisation immédiate de la coronarographie chez les patients ayant fait un ACR-EH avec ou sans ST+ à l'électrocardiogramme.

Notre étude a inclus tous les patients pris en charge pour ACR-EH (237 patients) et adressés directement en salle de coronarographie après récupération d'une activité cardiaque, répartis en deux sous-groupes : ACR-EH-ST+ (124 patients) et ACR-EH-ST- (113 patients). A 30 jours, 43% des patients du groupe ACR-EH-ST+ et 57% des patients du groupe ACR-EH-ST- étaient décédés ( $p<0,05$ ). La réalisation en urgence de la coronarographie post ACR-EH retarde l'admission en réanimation et la mise en place des mesures de neuroprotection (temps moyen de transfert de 100 minutes), ce qui pourrait expliquer en partie la surmortalité du groupe ACR-EH-ST-, chez qui seulement 21% de lésions coronaires coupables ont été retrouvées. L'âge et l'absence d'un rythme choquable sont les seuls facteurs qui restent statistiquement associés à la mortalité en analyse multivariée dans notre étude.

La prise en charge des ACR-EH suspects d'une étiologie cardiaque dans notre centre est cohérente avec les résultats des dernières recommandations et études. Le recours à la coronarographie en urgence semble plus bénéfique chez les patients avec sus décalage post resuscitation. Notre étude n'a pas réussi à identifier de nouveaux facteurs prédictifs permettant de mieux sélectionner les patients avec un ST- post ACR-EH pouvant bénéficier de la coronarographie en urgence avant l'admission en réanimation.

**Mots clés :** Arrêt cardiaque extrahospitalier, sous-décalage, sus-décalage, coronarographie, lésion coronaire coupable, neuroprotection, mortalité toute cause

### **Jury :**

Président du Jury : Professeur Fabrice IVANES

Directeur de thèse : Professeur Denis ANGOULVANT

Membres du Jury : Professeur Antoine GUILLO

Docteur Christophe SAINT ETIENNE

Docteur Maëva GOURRAUD

Date de soutenance : 7 septembre 2023